

Advances in the management of pancreatic cancer

Marco Del Chiaro,^{1,2} Toshitaka Sugawara,^{1,3} Sana D Karam,^{2,4} Wells A Messersmith,^{2,5}



¹Division of Surgical Oncology, Department of Surgery, University of Colorado School of Medicine, Aurora, CO, USA

²University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, CO, USA

³Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan

⁴Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO, USA

⁵Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA

Correspondence to:

M Del Chiaro
marco.delchiaro@cuanschutz.edu

Cite this as: *BMJ* 2023;383:073995
<http://dx.doi.org/10.1136/bmj-2022-073995>

Series explanation: State of the Art Reviews are commissioned on the basis of their relevance to academics and specialists in the US and internationally. For this reason they are written predominantly by US authors.

Abstract

Pancreatic cancer remains among the malignancies with the worst outcomes. Survival has been improving, but at a slower rate than other cancers. Multimodal treatment, including chemotherapy, surgical resection, and radiotherapy, has been under investigation for many years. Because of the anatomical characteristics of the pancreas, more emphasis on treatment selection has been placed on local extension into major vessels. Recently, the development of more effective treatment regimens has opened up new treatment strategies, but urgent research questions have also become apparent. This review outlines the current management of pancreatic cancer, and the recent advances in its treatment. The review discusses future treatment pathways aimed at integrating novel findings of translational and clinical research.

Introduction

Pancreatic cancer has been considered a deadly disease with a very small probability of long term survival.¹ Despite slow progress, long term survival rates have greatly improved, especially for resected patients. From 1975 to 2011, the five year survival for resected pancreatic cancer improved from 1.5% to 17.4%.² However, more recent data show that five year survival for all pancreatic cancers between 2012-18 reached only 11.5% in the United States.³

As a systemic disease, the changes in the survival of patients with pancreatic cancer have been affected most by the improvements in systemic treatments.⁴ Consequently, the anatomical factors influencing the resectability of pancreatic cancer, which are defined in the National Comprehensive Cancer Network (NCCN) clinical practice guidelines,⁶ have diminished in importance owing to better local and systemic control with higher response rates.

This review summarizes and contextualizes recent studies on the management of pancreatic cancer, and discusses potential treatments that are on the horizon. A detailed discussion of the preclinical or translational studies of diagnosis tools, drugs, and procedures is outside the scope of this review.

Sources and selection criteria

We searched Pubmed, the Cochrane database, and the Central Register of Controlled Trials (clinicaltrials.gov) between January 2000 and December 2022 for English language literature. We used the following keywords and keywords combinations: “pancreatic cancer”, “molecular characteristics”, “biology”, “resectability”, “metastatic”, “treatment”, “surgery”, “chemotherapy”, “radiation therapy”, “immunotherapy”, “prevention”, “precursor”, and “risk factor”. We also included the NCCN clinical practice guidelines,⁶ the European Society for Medical Oncology (ESMO) clinical practice

guidelines,⁷ and the clinical practice guidelines from the Japan Pancreas Society.⁸ We included studies based on the level of evidence; randomized controlled trials, meta-analyses, systematic reviews, and large retrospective cohort studies were prioritized. Meta-analyses included retrospective and prospective studies unless otherwise specified. We prioritized the most recent studies and excluded narrative reviews, case series, and case reports. We included additional landmark studies published before January 2000, as well as after December 2022.

Epidemiology

Pancreatic cancer is reported to account for 495 773 new cases and 466 003 deaths worldwide as of 2020, with the incidence and mortality rates stable or slightly increased in many countries.⁹ In the US, the estimated incidence of pancreatic cancer is increasing, with more than 50 000 new cases in 2020. Mortality rates have also increased moderately in men, to 12.7 per 100 000 men in 2020; but have remained stable in women, ranging from 9.3 to 9.6 per 100 000 women. Accordingly, pancreatic cancer is the third most common cause of cancer related death in 2023, and is predicted to become the second leading cause of cancer mortality by 2040.^{3 10}

Clinical presentation/features

Symptoms of pancreatic cancer are mostly non-specific, and generally manifest after the tumor has grown and metastasized. In a multicenter prospective study of 391 patients who were referred for suspicion of pancreatic cancer (119 had pancreatic cancer), the most common initial symptoms were decreased appetite (28%), indigestion (27%), and change in bowel habits (27%).¹¹ The initial symptoms were similar between the pancreatic cancer group and the non-cancer group, though several subsequent symptoms were associated with pancreatic cancer:

jaundice (49% v 12%), fatigue (51% v 26%), decreased appetite (48% v 26%), weight loss (55% v 22%), and change in bowel habits (41% v 16%).

Risk factors

Box 1 summarizes the risk factors for pancreatic cancer. Research is continuing into subtypes and modifiers of familial syndromes.

Precancerous lesion

Molecular research has proposed two evolutionary models of pancreatic cancer: the classic “stepwise” model, with gradual accumulation of driver gene mutations, and the novel “punctuated” model,²⁴ in which driver gene mutation occurs simultaneously by chromosomal rearrangements. The stepwise model is characterized by tumor evolution from a precancerous lesion (low grade or high grade dysplasia) to invasive cancer, and is believed to be the main evolutionary pattern. Pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasms (IPMNs) are well known precancerous lesions. By contrast to PanIN, which is a microscopic neoplastic lesion, IPMNs can be detected and followed by imaging studies. Consequently, extensive studies have been conducted to evaluate the association between imaging findings and pathological findings of IPMNs. Branch duct IPMNs have been reported to have a low malignant nature (1.0% patient years),²⁵ but harbor a risk of concomitant pancreatic cancer (0.8%).²⁶ Main duct IPMNs have been reported to be

a high risk factor for pancreatic cancer (odds ratio 5.66).²⁷

Screening and early detection

Because early stage (ie, stage I, T1NOM0) disease or precancerous lesions are more likely to be curable, the goal of screening or surveillance for pancreatic cancer is to detect lesions of 2 cm or smaller, or patients with high grade dysplasia.²⁸ Several studies have estimated an interval of several years between a high grade dysplasia lesion (high grade PanIN and IPMN) and invasive cancer, which can give opportunities for early detection and intervention: 2.3-11 years for high grade PanIN,^{29 30} and more than three years for high grade IPMN.³¹ The International Cancer of the Pancreas Screening (CAPS) consortium has published consensus guidelines about screening for high risk patients who have high risk germline mutations or relatives with pancreatic cancer, or both.²⁸ A recent prospective cohort study (CAPS5) from the CAPS group including 1461 high risk patients showed positive results of surveillance²⁵; seven of nine patients (77.8%) who developed pancreatic cancer had stage I cancer. However, only three of the eight patients (37.5%) who had IPMNs with worrisome features had high grade dysplasia (five had low grade dysplasia). A multicenter retrospective study (n=2552) of the CAPS consortium showed that 13 of the 28 patients (46.4%) who developed high grade dysplasia or cancer developed the new lesion during the scheduled examination interval.³² Regarding IPMNs in the general population, a recent retrospective study showed that only 177 of 1439 patients with resected IPMN (12.3%) had high grade dysplasia, and 497 (34.5%) had a diagnosis of invasive cancer.³³ These results suggest that a novel strategy distinct from current guidelines^{34 35} is needed for IPMN lesions, and new diagnostic tests are needed to detect tiny tumors.

The United States Preventive Services Task Force (USPSTF)³⁶ recommends avoiding pancreatic cancer screening in asymptomatic adults with average risk, considering the relatively low prevalence (estimated 64 050 new cases in 2023).³⁶ However, the USPSTF does not discuss screening in patients with risk factors of age and lifestyle, and neither do the consensus guidelines of the CAPS consortium. A risk assessment model including all known risk factors (box 1) could help to identify good candidates for pancreatic cancer screening.

Carbohydrate antigen 19-9 (CA19-9) is a cell surface tetrasaccharide often elevated in pancreatic cancer, as well as in other cancers and some benign diseases. Historically, CA19-9 has not been used for early detection, owing to its insufficient sensitivity for early stage pancreatic cancer.³⁷ We also know that 5-10% of the population does not synthesize CA19-9, owing to a deficiency of a fucosyltransferase enzyme. However, a recent large retrospective cohort study showed that CA19-9 levels increase from two years before diagnosis of pancreatic cancer, with a sensitivity of 50% and specificity of 99% within 0-6

Box 1: Factors that increase the risk of pancreatic cancer

Family history

- Up to 10% of all pancreatic cancers are estimated to be familial (meaning that at least two first degree relatives have pancreatic cancer)
- Patients who have two first degree relatives with pancreatic cancer have a standardized incidence ratio of 6.4 (lifetime risk 8-12%)¹²
- Patients who have three first degree relatives with pancreatic cancer have a standardized incidence ratio of 32.0 (lifetime risk 40%)¹²
- Approximately 20% of these families have a germline mutation that is already reported and known

Germline mutation and hereditary syndrome

- LKB1/STK11: Peutz-Jeghers syndrome; relative risk 132¹³
- CDKN2A/p16: familial atypical multiple mole melanoma syndrome; relative risk 13-22¹⁴
- PRSS1/CPA1/CTRC/SPINK1: hereditary pancreatitis; relative risk 53-87¹⁵
- BRCA1 and BRCA2: hereditary breast ovarian cancer syndrome; relative risk 2 and 10, respectively¹⁶
- MLH1/MSH2/MSH6/PMS2: Lynch syndrome; relative risk up to 8.6¹⁷
- PALB2/ATM: relative risk unknown

Lifestyle factors

- Smoking: current smoker relative risk 1.8; former smoker relative risk 1.2¹⁸
- Obesity: five unit increment in body mass index relative risk 1.10¹⁹
- Diabetes mellitus*: relative risk 1.94²⁰
- Chronic pancreatitis: relative risk 16.16²¹

*Diabetes mellitus is also a symptom of pancreatic cancer; new onset diabetes in older people could be an early sign of pancreatic cancer and can lead to early diagnosis.²² The association between diabetes and pancreatic cancer is currently undergoing further research.²³

months before diagnosis in early stage disease. In addition, in cases with CA19-9 levels below the cut-off value, the combination of LRG1 and TIMP1 could complement CA19-9, leading to the identification of cases missed by CA19-9 alone.³⁸ Novel tests (ie, cytology³⁹ and DNA alterations⁴⁰) using pancreatic juice and cystic fluid have been reported to play a promising role in identifying high grade dysplasia and invasive cancer with high specificity. However, the sensitivity of these tests is low (<50%). Extensive studies have investigated the role of liquid biopsy in pancreatic cancer: circulating tumor cells,⁴¹ circulating tumor DNA,^{42,43} microRNA,⁴⁴ exosomes,⁴⁵ and methylation signatures of cell free DNA.⁴⁶ Although these new biomarkers show promise, many problems remain unsolved with regard to standardization of testing techniques and cut-off values (table 1). However, advances in this field could increase survival drastically.

Diagnosis and evaluation

The performance of diagnosis tools is summarized in box 2.

Imaging study for evaluation

CT (computed tomography) is the standard tool to evaluate the extent of the primary tumor and determine its anatomical resectability. Two meta-analyses showed similar performance of CT (sensitivity 70%, specificity 95%) and MRI (magnetic resonance imaging) (sensitivity 65%, specificity 95%) in the diagnosis of vascular involvement.^{50,51} A meta-analysis showed that endoscopic ultrasound performed similarly to CT in evaluating vascular

invasion.⁵² A multimodal approach (ie, CT plus MRI plus endoscopic ultrasound) provides a better assessment of resectability. Several studies have attempted to evaluate the response to chemotherapy with imaging studies to determine the course of treatment (ie, proceeding to surgery or continuing chemotherapy). However, the currently used response evaluation criteria in solid tumors (RECIST) are not sufficient to reassess local response after chemotherapy in pancreatic cancer, especially regarding the involvement of vessels. Distinguishing scar areas with fibrosis that occur with treatment from cancer cell death from viable tumor associated desmoplasia is challenging; both are common in pancreatic cancer. A meta-analysis including six studies with 217 patients showed the difficulty of using CT scans to predict margin negative resection after preoperative treatment; the sensitivity was 81% and specificity was as low as 42%.⁵³ MRI^{54,55} and fluorodeoxyglucose PET (positron emission tomography)/CT or PET/MRI⁵⁶ have been reported to be associated with the pathological response to preoperative treatment, though the ability to evaluate the vessel involvement and resectability is unclear. However, it should also be noted that even in the setting of histological response assessment, moderate inter-rater reliability differences have been reported between pathologists.⁵⁷

Biomarker for evaluation

CA19-9 has been used to assess response to treatment and predict prognosis. A meta-analysis showed that CA19-9 was associated with the effect of preoperative treatment, and suggested that either normalization

Table 1 | Summary of novel techniques for diagnosis and early detection of pancreatic cancer

Technique	Identification target	Feature	Usage	Data in pancreatic cancer		Areas needing improvement
				Outcome	Results (95% CI)	
Circulating tumor cell	EpCAM+, CD45-, CK+, DAPI+, MUC1	<ul style="list-style-type: none"> Tumor cells that shed from tumors into circulation Associated with metastasis 	<ul style="list-style-type: none"> Prognosis evaluation Early detection Drug response 	Detection rate (%) Overall/FDA approved*	65 (55 to 75)/ 26 (14 to 38)	<ul style="list-style-type: none"> Detection rate Molecular tests of circulating tumor cells
ctDNA, cfDNA	Somatic mutation†	<ul style="list-style-type: none"> Short chain DNA from tumor cells (micrometastasis) Up to 1% of cfDNA 	<ul style="list-style-type: none"> Early detection Residual disease Drug response 	OS of CTC+ Detection in RPC (%) OS/RFS of ctDNA+ in localized cancer	HR 1.82 (1.61 to 2.05) 8.3 to 68.6 HR 2.04 (1.29 to 3.21)/ HR 2.27 (1.59 to 3.24)	<ul style="list-style-type: none"> Detection rate Using multigene panels
miRNA	miRNA‡	<ul style="list-style-type: none"> Regulates gene expression Has oncogenic or tumor suppressive functions 	<ul style="list-style-type: none"> Early detection Prognosis evaluation Drug response 	Diagnosis of PC Prognostic value	AUC 0.81 Under investigation	<ul style="list-style-type: none"> Validated panel Number/quality of studies
Exosomes (produced by tumor cells)	Size, density, surface protein§	<ul style="list-style-type: none"> Contain protein and nucleic acids Produced continuously by tumors from a very early stage 	<ul style="list-style-type: none"> Early detection Prognosis evaluation Drug response 	Early detection Progression Mortality in RPC	Under investigation HR 3.33 (2.33 to 4.77) HR 5.55 (3.24 to 9.49)	<ul style="list-style-type: none"> Detection rate Studies on nucleic acids
Methylation (nucleic acids in blood or exosome)	DNA¶, (miRNA)	<ul style="list-style-type: none"> Related to carcinogenesis Organ specific, tissue specific, and/or tumor specific 	<ul style="list-style-type: none"> Early detection Prognosis evaluation Drug response 	Diagnosis of PC (%) Sensitivity/specificity Prognosis	Range 50.9-100/ 75-93.5 Under investigation	<ul style="list-style-type: none"> Validated panel Number/quality of studies

AUC=area under curve; CK=cytokeratin; cfDNA=cell free DNA; ctDNA=circulating tumor DNA; DAPI= 4',6-diamidino-2-phenylindole; EpCAM= epithelial cell adhesion molecule; FDA= Food and Drug Administration; HR=hazard ratio; miDNA=micro DNA; MUC1=mucin 1; OS=overall survival; PC=pancreatic cancer; RFS=recurrence free survival; RPC: resectable pancreatic cancer.

*Combination of EpCAM+, CD45-, and CK+.⁴¹

†RAS, TP53, CDKN2A, SMAD4, KIT, PDGFR, MET, BRAF, PIK3CA, etc.

‡Dozens of miRNAs are under investigation.

§Tetraspanins (ie, CD9, CD63, and CD81), etc.

¶ADAMTS1, ADAMTS2, ALX4, BNC1, CDKN2B, DACT-2, HIC1, HOXA1, HYAL2, LRFN5, MLH1, NEUROG1, NPTX2, PCDH10, PENK, PXDN, RUNX3, SEMA5A, SEPT9v2, SPARC, SPSB4, SST, UCHL1, etc.

Box 2: Imaging study and biomarker for diagnosis of pancreatic cancer

- CT (computed tomography) is the standard modality; accuracy 89% (95% confidence interval 85 to 93)⁴⁷
- MRI (magnetic resonance imaging) has a similar performance to CT; accuracy 90% (95% confidence interval 86 to 94)⁴⁷
- PET (positron emission tomography) has a worse performance; accuracy 84% (95% confidence interval 79 to 89)⁴⁷
- Endoscopic ultrasound has a similar performance to CT; accuracy 89% (95% confidence interval 87 to 92)⁴⁷
- Endoscopic ultrasound can identify masses that are indeterminate by CT; accuracy 75% (95% confidence interval 67 to 82)⁴⁸
- CA19-9 is the most widely used and validated biomarker; area under curve 0.83-0.9¹⁴⁹

of CA19-9 or a decrease of more than 50% from the baseline level are positive predictors of survival.⁵⁸ A recent retrospective study analyzing the combination of CT and CA19-9 showed a good predictive performance of survival after chemoradiotherapy.⁵⁹ However, the optimal evaluation of response to treatment remains unclear. The ability of liquid biopsy (table 1) to detect minimal residual disease following all planned treatment could identify a new subset of patients who require further treatment, and would lead to a true precision medicine approach, as has been achieved with other cancer types.⁶⁰

Cancer cell intrinsic and tumor microenvironment factor

Transcriptional studies have proposed several classifications of pancreatic cancer. A recent bioinformatic study⁶¹ from The Cancer Genome Atlas research network supported the two subgroup model⁶²: the basal-like subtype, which has low levels of GATA6 expression, and the classic subtype. In a prospective translational trial, the basal-like subtype was reported to be associated with a poor response to chemotherapy with FOLFIRINOX (combined leucovorin calcium (folinic acid), fluorouracil, irinotecan, and oxaliplatin) for patients with advanced cancer.⁶³ However, a more recent study using single cell analysis suggested that pancreatic cancer consists of a mixture of tumor cells with both molecular subtypes, and the composition is plastic and unstable.⁶⁴

In addition to the cancer cells themselves, the tumor microenvironment has been identified as being an essential factor associated with tumor progressions and tumor immunity. Pancreatic cancer is notorious for poor tumor cellularity and an abundant, fibrotic extracellular matrix. Although the dense extracellular matrix has been known to impair drug delivery and immune cell migration, it appears to have an essential role in maintaining the tumor microenvironment and supporting the progression of tumor cells.⁶⁵ Therefore, the efficacy of controlling the extracellular matrix by targeting its components (ie, collagen, cancer associated fibroblasts, and hyaluronan) and cytokines (ie, transforming growth factor β and sonic hedgehog) has been evaluated.

Treatment

Figure 1 outlines the current management for pancreatic cancer based on the anatomic resectability of the tumor, with the first consensus statement defined in 2009,⁶⁶ before the advent of more effective systemic treatments. In primary resectable disease, upfront surgery followed by adjuvant chemotherapy has been considered the standard of care. By contrast, for borderline resectable and locally advanced diseases, preoperative treatment is generally proposed, because of the high likelihood of micrometastasis and the low likelihood of margin negative resection in these tumors.⁶⁷ However, the improvement of medical treatment is challenging this concept; neoadjuvant treatment for resectable diseases is under investigation. At present, the recommendation is that the decision for treatment should be made at a multidisciplinary conference at a high volume center.

Systemic treatment

The standard drug treatment for systemic treatment is still cytotoxic chemotherapy, and the efficacy of targeted treatment or immunotherapy remains unproven. Table 2 summarizes the clinical trials of medical treatment.

Systemic treatment for metastatic disease

Gemcitabine became the standard chemotherapy drug for pancreatic cancer more than 20 years ago. In 1997, gemcitabine showed clinical benefit and marginally improved overall survival compared with fluorouracil (median survival 5.65 v 4.41 months) in a small randomized controlled trial that included 63 patients in each arm.⁶⁸ Consequently, several trials were performed investigating combinations with gemcitabine.⁶⁹⁻⁷¹ However, most studies did not show a significant improvement in overall survival; the combinations tested included fluorouracil,⁷² irinotecan,⁷³ oxaliplatin,^{74 75} cisplatin,^{76 77} and capecitabine.⁷⁸⁻⁸⁰ Unfortunately, the addition of targeted treatment to gemcitabine based chemotherapy also did not show a survival benefit, with any of tipifarnib,⁸¹ cetuximab,⁸² bevacizumab,⁸³ axitinib,⁸⁵ and vandetanib.⁸⁶ In 2011, a landmark randomized phase 2/3 trial (PRODIGE 4/ACCORD 11) defined a new standard chemotherapy for metastatic pancreatic cancer.⁷¹ This multicenter trial enrolled 171 patients in each arm and showed a significant improvement in survival, with a median overall survival of 11.1 months in the FOLFIRINOX group, compared with 6.8 months in the gemcitabine group (hazard ratio 0.57; 95% confidence interval 0.45 to 0.73). FOLFIRINOX also had a higher response rate (31.6%) than gemcitabine (9.4%). Subsequently, the MPACT trial, a large randomized phase 3 study, showed another cytotoxic combination option (gemcitabine/nab-paclitaxel) for metastatic pancreatic cancer.⁸⁷ This study included 861 patients, and showed that gemcitabine/nab-paclitaxel improved survival compared with gemcitabine alone (median survival 8.5 v 6.7 months; hazard ratio 0.72; 95% confidence interval 0.62 to 0.83). FOLFIRINOX




Fig 1 | Current management for pancreatic cancer. CA19-9=carbohydrate antigen 19-9

and gemcitabine/nab-paclitaxel have formed the cytotoxic “backbones” for multiple clinical trials.

Nanoliposomal irinotecan is a drug encapsulating irinotecan sucrosfate salt payload in tiny pegylated liposomal particles, which theoretically can enhance the exposure of irinotecan to tumor cells. A recent randomized phase 3 trial (NAPOLI-3) enrolled 770 patients with metastatic pancreatic cancer and compared NALIRIFOX (combined liposomal irinotecan, fluorouracil, folinic acid, and oxaliplatin) (n=383) to gemcitabine/nab-paclitaxel (n=387) as the first line treatment.⁸⁸ Preliminary results showed an improved overall survival (median 11.1 v 9.2 months; hazard ratio 0.84; 95% confidence interval 0.71 to 0.99), which was the primary endpoint, and an improved progression free survival (7.4 v 5.6 months; 0.70; 0.59 to 0.84). For Asian populations, S-1 (an oral fluoropyrimidine derivative) is another treatment option, after it showed non-inferiority to gemcitabine for advanced pancreatic cancer in a randomized phase 3 study (GEST).⁸⁹

Second line systemic treatment for advanced disease

Second line regimens after gemcitabine based chemotherapy for advanced pancreatic cancer have been studied in several trials. The CONKO-003 randomized phase 3 trial showed that the addition

of oxaliplatin to folinic acid and fluorouracil (5FU/LV) significantly improved overall survival (median 5.9 v 3.3 months, hazard ratio 0.66; 95% confidence interval 0.48 to 0.91).⁹⁰ By contrast, another randomized phase 3 trial (PANCREOX) found a deleterious effect on survival of oxaliplatin (mFOLFOX6) over infusional fluorouracil/leucovorin (hazard ratio 1.78; 95% confidence interval 1.08 to 2.93) in the second line setting.⁹¹

A large randomized phase 3 trial (NAPOLI-1) investigated the efficacy of nanoliposomal irinotecan to 5FU/LV for metastatic disease after gemcitabine based treatment.⁹² The results showed that nanoliposomal irinotecan plus 5FU/LV incrementally improved survival compared with 5FU/LV (6.1 v 4.2 months, hazard ratio 0.67; 95% confidence interval 0.49 to 0.92). Patients who received nanoliposomal irinotecan monotherapy, however, had similar survival to those who received 5FU/LV (4.9 v 4.2 months, 0.99; 0.77 to 1.28). Further studies on second line regimens after FOLFIRINOX or gemcitabine/nab-paclitaxel are warranted.

Maintenance systemic treatment for advanced disease

A poly adenosine diphosphate ribose polymerase (PARP) inhibitor was investigated as the maintenance

Table 2 | Summary of key studies of medical treatment of pancreatic cancer

Study setting	Study	Study type	Arm (N)	Primary end point	Overall survival		Secondary end point	DFS/RFS/PFS		ORR (%)
					Months	HR (95% CI)		Months	HR (95% CI)	
Metastatic	PRODIGE (2011)	RCT, phase 2/3	FFX (171)	OS	11.1	0.57 (0.45 to 0.73)	PFS	6.4	0.47 (0.37 to 0.59)	31.6
			Gemcitabine (171)		6.8			3.3		9.4
Metastatic	MPACT (2013)	RCT, phase 3	GnP (431)	OS	8.5	0.72 (0.62 to 0.83)	PFS	5.5	0.69 (0.58 to 0.82)	23.0
			Gemcitabine (430)		6.7			3.7		7.2
Metastatic, second line*	NAPOLI-1 (2016)	RCT, phase 3	Nal-IRI + 5-FU/LV (117)	OS	6.1	0.67 (0.49 to 0.92)	PFS	3.1	0.56 (0.41 to 0.75)	16.2
			5-FU/LV (119)		4.2			1.5		0.8
Metastatic maintenancet	POLO (2019, 2022)	RCT, phase 3	Olaparib (92)	PFS	19.0	0.83 (0.56 to 1.22)	OS	7.4	0.53 (0.35 to 0.82)	23.1
			Placebo (62)		19.2			3.8		11.5
Adjuvant	CONKO-001 (2007)	RCT, phase 3	Gemcitabine (179)	DFS	22.1	18.4 to 25.8‡	OS	13.4	11.4 to 15.3‡	—
			Observation (175)		20.2			6.9		6.1 to 7.8†
Adjuvant	ESPAC-4 (2017)	RCT, phase 3	GemCap (364)	OS	28.0	0.82 (0.68 to 0.98)	RFS	13.9	0.86 (0.73 to 1.02)	—
			Gemcitabine (366)		25.5			13.1		—
Adjuvant	PRODIGE-24 (2018, 2022)	RCT, phase 3	mFFX (247)	DFS	53.5	0.68 (0.54 to 0.85)	OS	21.4	0.66 (0.54 to 0.82)	—
			Gemcitabine (246)		35.5			12.8		—
Adjuvant	APACT (2022)	RCT, phase 3	GnP (432)	DFS	40.5	0.82 (0.68 to 0.996)	OS	19.4	0.88 (0.73 to 1.06)	—
			Gemcitabine (434)		36.2			18.8		—
Neoadjuvant§	PREOPANC-1 (2020, 2022)	RCT, phase 3	Gemcitabine plus RT (119)	OS	15.7	0.73 (0.56 to 0.96)	DFS	8.1	0.69 (0.53 to 0.91)	—
			Upfront surgery (127)		14.3			7.7		—
Locally advanced	Suker et al (2016)	Meta-analysis	FFX ± RT (315)	OS	24.2	21.7 to 26.8‡	PFS	15.0	13.8 to 16.2‡	25.9 (78.4)¶
Locally advanced	LAPACT (2020)	RCT, phase 2	GnP (107)	Treatment failure**	18.8	—	OS	10.9	—	15.9 (41.2)¶

DFS=disease free survival; 5-FU/LV=fluorouracil and folinic acid; FFX=folinic acid, fluorouracil, irinotecan hydrochloride, and oxaliplatin; GemCap=gemcitabine and capecitabine; GnP=gemcitabine and nab-paclitaxel; HR=hazard ratio; mFOLFIRINOX=modified FOLFIRINOX; nal-IRI=nanoliposomal irinotecan; ORR=objective response rate; OS=overall survival; PFS=progression free survival; RCT=randomized controlled trial; RT=radiotherapy.

*Patients with distant metastases who had progression after previous gemcitabine based treatment given for localized, locally advanced, or metastatic cancer.

†Patients with germline mutations in BRCA1 or BRCA2, who had received at least 16 weeks of continuous platinum based chemotherapy as the first line treatment for metastatic pancreatic cancer, were enrolled.

‡95% confidence interval of survival time is shown.

§Patients with resectable or borderline resectable cancers were enrolled.

¶Resection rate (margin negative rate) is shown.

**Defined as the time after the first dose of gemcitabine and nab-paclitaxel until disease progression (assessed by the investigator), death by any cause, or the start of a non-protocol defined treatment.

treatment in patients who had germline loss-of-function mutations in BRCA1 or BRCA2, and platinum sensitive advanced disease. A randomized double blind phase 3 trial (POLO) showed no survival benefit of olaparib (n=62) compared with placebo (n=92) (median overall survival 19.0 v 19.2 months; hazard ratio 0.83; 95% confidence interval 0.56 to 1.22), but did show an improvement in progression free survival, which resulted in US Food and Drug Administration approval.^{93 94} Another PARP inhibitor, niraparib, combined with an anti-CTLA-4 (ipilimumab) drug, showed a median overall survival of 17.3 months (95% confidence interval 12.8 to 21.9 months) in a phase 1b/2 trial.⁹⁵ Maintenance treatment for non-BRCA mutated patients with metastatic diseases following FOLFIRINOX was evaluated in the PANOPTIMOX-PRODIGE 35 phase 2 trial.⁹⁶ This study randomly assigned 273 patients to six month FOLFIRINOX (n=91), four month FOLFIRINOX followed by leucovorin/5-FU maintenance (n=92), or a sequential treatment alternating gemcitabine and FOLFIRI.3 every two months (n=90). The results showed a comparable six month progression free survival rate and median progression free survival in the maintenance arm eliminating oxaliplatin (44%, 5.7 months), and the

worst survival in the gemcitabine/FOLFIRI approach (34%, 4.5 months) compared with the six month FOLFIRINOX arm (47%, 6.3 months).

Adjuvant systemic treatment

Adjuvant systemic treatment is recommended for all eligible resected patients. The first large randomized phase 3 trial that showed the survival benefit of adjuvant chemotherapy was the ESPAC-1 trial, which assigned resected patients (n=289) to 5-FU/LV versus control.^{4 97} Adjuvant chemotherapy prolonged the median overall survival by 4.6 months (hazard ratio 0.71; 95% confidence interval 0.55 to 0.92).⁴ The CONKO-001 randomized phase 3 trial showed that adjuvant gemcitabine (n=179) improved overall survival compared with observation (n=172) (median 22.8 v 20.2 months; hazard ratio 0.76; 95% confidence interval 0.61 to 0.95).⁹⁸ When 5FU/LV and gemcitabine were compared head-to-head, no difference in overall survival was found, but gemcitabine had less toxicity in the ESPAC-3 randomized phase 3 trial.⁹⁹ Subsequently, multiple trials tried to find a new effective combination treatment with gemcitabine. A randomized phase 3 trial combining erlotinib with gemcitabine was negative,¹⁰⁰ but the addition of capecitabine had a

Box 3: Comparison between robotic pancreaticoduodenectomy and open pancreaticoduodenectomy or laparoscopic pancreaticoduodenectomy**Robotic pancreaticoduodenectomy (v open pancreaticoduodenectomy)¹³⁴⁻¹³⁶ | Robotic pancreaticoduodenectomy (v laparoscopic pancreaticoduodenectomy)^{135 137 138}**

- RO resection: Comparable^{135 136} or higher¹³⁴ | Comparable¹³⁵
- Lymph nodes harvested: Comparable^{135 136} or more¹³⁴ | Comparable¹³⁵ or more^{137 138}
- Operating time: Longer¹³⁴⁻¹³⁶ | Comparable^{135 137 138}
- Estimated blood loss: Less¹³⁴⁻¹³⁶ | Comparable¹³⁸ or less^{135 137}
- Conversion rate: Not applicable | Lower^{137 138}
- Overall mortality rate: Comparable¹³⁴ or lower¹³⁶ | Comparable¹³⁸
- Overall morbidity rate: Comparable^{134 135} or lower¹³⁶ | Comparable^{135 137 138}
- Surgical site infection: Less^{134 135} | Comparable^{135 138}
- Pancreatic fistula: Comparable^{134 135} or less¹³⁶ | Comparable^{135 137 138}
- Hemorrhage: Comparable¹³⁵ | Comparable¹³⁵
- Delayed gastric emptying: Comparable^{134 136} or less¹³⁵ | Comparable^{135 137 138}
- Length of stay: Comparable^{134 135} or longer¹³⁶ | Comparable^{135 137} or shorter¹³⁸

survival benefit over gemcitabine alone (28.0 v 25.5 months; 0.82; 0.68 to 0.98) in the ESPAC-4 phase 3 trial.¹⁰¹ However, this combination treatment was short lived; FOLFIRINOX drastically changed the survival of patients and became the new standard regimen for adjuvant treatment. The PRODIGE 24/ CCTG PA6 phase 3 trial randomly assigned 493 resected patients to receive adjuvant modified (dose reduced) FOLFIRINOX (mFOLFIRINOX) or gemcitabine for 24 weeks. The mFOLFIRINOX group (n=247) showed a significantly improved median overall survival (53.5 v 35.5 months; 0.68; 0.54 to 0.85).^{5 102} By contrast, gemcitabine/nab-paclitaxel failed to show a survival benefit over gemcitabine alone in a randomized phase 3 trial (APACT).¹⁰³ It did not meet the primary endpoint of disease free survival by central review,¹⁰³ although overall survival improved marginally in the gemcitabine/nab-paclitaxel group (40.5 v 36.2 months; 0.82; 0.680 to 0.996). In Asia, S-1 is the standard regimen,

Box 4: Characteristics of radiotherapy for pancreatic cancer by types and doses

3

dimensional conformal radiation therapy (3D-CRT)

- Using multiple beams shaped to conform to a tumor that is identified its size, shape, and location by 3D imaging (ie, CT, MRI)
- Generally used dose: * 45.0-56.0 Gy in 1.75-2.20 Gy fractions

Image guided radiation therapy (IGRT)

- An adjunctive technique to adjust the tumor location difference by using 3D imaging (ie, CT, MRI) performed immediately before each radiation treatment

Intensity modulated radiation therapy (IMRT)

- Possible to adjust the irradiation intensity within a target volume
- Possible to deliver a concentrated dose to a tumor and better spare the normal tissue
- Generally used dose: * 45.0-56.0 Gy in 1.75-2.20 Gy fractions

Stereotactic body radiotherapy (SBRT)

- Accurately irradiate a tumor with high dose radiation in three dimensions from multiple directions
- High local control rate, comparable toxicity¹⁴¹
- Generally used dose: * 30.0-40.0 Gy in 6.00-8.00 Gy fractions

*Based on the ASTRO clinical practice guideline¹⁴²

based on the results of a randomized phase 3 trial.¹⁰⁴ The role of adjuvant treatment after neoadjuvant chemotherapy and surgical resection is still debatable. A recent large retrospective study showed a potential benefit in survival for patients able to receive adjuvant chemotherapy after neoadjuvant and surgery.¹⁰⁵

Neoadjuvant systemic treatment

One of the underpinnings of neoadjuvant treatment is that 36% of patients with pancreatic cancer are unable to receive adjuvant chemotherapy after resection,¹⁰⁶ and surgical resection alone does not achieve long term survival for most patients. The rationale for neoadjuvant treatment is to increase the dose intensity and tolerance of planned systemic treatment before patients are weakened by surgery, and to avoid delayed treatment of micrometastatic disease, which is the main cause of mortality.¹⁰⁷ Two prospective single arm phase 2 studies showed the safety of neoadjuvant gemcitabine plus a platinum based drug.^{108 109}

The only published phase 3 trial of neoadjuvant systemic treatment (PREOPANC-1) randomly assigned 246 patients with resectable (54.1%) or borderline resectable disease (45.9%) to neoadjuvant chemoradiotherapy (n=119) or upfront surgery (n=127).^{110 111} The neoadjuvant chemoradiotherapy arm received three cycles of neoadjuvant gemcitabine with 36 Gy radiotherapy in 15 fractions and four cycles of adjuvant gemcitabine, whereas the upfront surgery arm received six cycles of adjuvant gemcitabine. Long term results showed a consistent survival benefit of neoadjuvant treatment regardless of the resectability of the primary tumors, for borderline resectable diseases (hazard ratio 0.67; 95% confidence interval 0.45 to 0.99) and resectable diseases (0.79; 0.54 to 1.16). However, the chemotherapy regimen (gemcitabine alone) was outdated. The recent ESPAC-5 phase 2 trial¹¹² randomly assigned 90 patients with borderline resectable diseases to neoadjuvant treatment (n=56), which included multiagent neoadjuvant chemotherapy and single agent chemoradiotherapy, or upfront surgery (n=33). It showed a better one year overall survival in the neoadjuvant treatment groups compared with the upfront surgery group (76% v 39%; hazard ratio 0.29; 95% confidence interval 0.14 to 0.60), although it did not provide evidence of the optimal regimen owing to the small sample size.

Regarding resectable diseases, one concern of neoadjuvant treatment is the possibility of disease progression during neoadjuvant treatment, which could cause patients to miss the opportunity for surgical resection. Indeed, the role of neoadjuvant treatment for resectable disease is still under investigation. A randomized phase 2 trial (PACT-15) showed that neoadjuvant chemotherapy with the PEFG regimen (cisplatin, epirubicin, fluorouracil, and gemcitabine) improved overall survival compared with adjuvant gemcitabine and adjuvant PEFG regimen for resectable disease.¹¹³ The Prep-02/

JSAP-05 phase 2/3 trial randomly assigned patients with resectable (about 80%) or borderline resectable diseases to one month neoadjuvant gemcitabine plus S-1 (n=182), or upfront surgery (n=180). Both arms received six month S-1 as the adjuvant treatment.¹¹⁴ The results showed improved overall survival in the neoadjuvant chemotherapy arm (36.7 v 26.6 months; hazard ratio 0.72; 95% confidence interval 0.55 to 0.94). Conversely, studies of FOLFIRINOX have not shown positive results.^{115 116} The SWOG S1505 phase 2 study showed equivalent efficacy of neoadjuvant mFOLFIRINOX versus nab-paclitaxel/gemcitabine for three months for resectable disease.¹¹⁵ The median overall survival in both arms (23.2 and 23.6 months) did not show improvement compared with previous trials of adjuvant treatment.

A recent phase 2 trial (NORPACT-1) randomly assigned 140 patients with resectable diseases to the neoadjuvant FOLFIRINOX arm (n=77) or the upfront surgery arm (n=63), and found no survival benefit of neoadjuvant FOLFIRINOX. However, the results have several problems. While not significant, the median survival was 13.4 months shorter (25.1 v 38.5 months) in the neoadjuvant FOLFIRINOX arm, despite the higher rates of node negative (NO) and margin negative (RO) resection in that arm. Given the high resection rate (n=63, 82%) despite the low completion rate of neoadjuvant chemotherapy (n=40, 52%), and the high rate of adjuvant chemotherapy other than FOLFIRINOX (75%) in the neoadjuvant group, it seems that the neoadjuvant

group did not receive sufficient FOLFIRINOX chemotherapy. In addition, whether two months is sufficient for neoadjuvant FOLFIRINOX is unclear. Three ongoing large randomized phase 3 trials might provide some insight into the optimal sequence and the number of cycles of FOLFIRINOX; two are recruiting patients (ALLIANCE-A021806 and PREOPANC-3), and one recently opened (NCT05529940). The first two trials plan to enrol more than 300 patients with resectable disease to assess the overall survival of perioperative FOLFIRINOX (eight cycles of neoadjuvant and four cycles of adjuvant) compared with adjuvant FOLFIRINOX (12 cycles). The NCT05529940 trial plans to enrol more than 600 patients and evaluate the two year survival of perioperative FOLFIRINOX (six cycles of neoadjuvant and six cycles of adjuvant) compared with adjuvant FOLFIRINOX (12 cycles).

Systemic treatment for locally advanced disease

After the positive results of FOLFIRINOX and gemcitabine/nab-paclitaxel for metastatic disease, several studies have investigated its efficacy in locally advanced diseases. A systematic review that analyzed 315 patients with locally advanced diseases from 11 studies between 1994 and 2015 showed that FOLFIRINOX was associated with a longer median overall survival of 24.2 months (95% confidence interval 21.7 to 26.8 months).¹¹⁷ The proportion of patients who underwent surgical resection after FOLFIRINOX ranged from 0-43%. A

Table 3 | Summary of key studies of radiotherapy for pancreatic cancer

Study	Study type, study setting	Arm (N)	Primary end point	Overall survival		Secondary end point	DFS/RFS/EFS/PFS		
				Months	95% CI		Months	95% CI	ORR (%)
ESPAC-1* (2001, 2004)	RCT, phase 3 Adjuvant	CRT, 20 Gy (145)	2 year survival	15.9	1.47 (1.10 to 1.95)†	DFS	10.7	8.8 to 15.5	—
		No RT (144)		17.9			15.2		
Van Laethem et al (2010)	RCT, phase 2 Adjuvant	Gem + RT, 50.4 Gy (45)	Feasibility, tolerability	24.3	20.5 to NR	OS, DFS	11.8	10.1 to 19.3	—
		Gemcitabine (45)		24.4			10.9		
Ma et al (2022)	RCT, phase 2 Adjuvant, stage 2	Gem + SBRT, 25 Gy (18)	RFS	15.0	0.56 (0.23 to 1.36)†	OS	5.3	0.80 (0.40 to 1.60)†	—
		Gemcitabine (20)		28.0			9.7		
Murphy et al (2018)	Phase 2 Neoadjuvant, borderline resectable	FFX + SBRT, 25 Gy (48)	RO resection	37.7	19.4 to NR	OS, PFS	14.7	10.5 to NR	32.0 (96.9)‡
Janssen et al (2021)	Meta-analysis Neoadjuvant, resectable/ borderline resectable	FFX + RT (161)	OS	22.4	11.0 to 37.7	PFS	28.4	18.0 to 48.6	63.1 (97.6)‡
		FFX (351)		21.6			13.7 to 28.0		71.9 (88.0)‡
A021501 (2022)	RCT, phase 2 Neoadjuvant, borderline resectable	mFFX + SBRT (55)	1.5 year survival	17.1	12.8 to 24.4	EFS§	10.2	6.7 to 17.3	—
		mFFX (65)		29.8			11.2 to 21.9		
LAP07 (2016)	RCT, phase 2 Locally advanced*	Gem based¶ + RT, 54 Gy (133)	OS by regimen	15.2	1.03 (0.79 to 1.34)†	OS/PFS by RT	9.9	0.78 (0.61 to 1.01)†	4.1 (61.1)‡
		Gem based¶ (136)		16.5			8.4		
LAPC-1 (2019)	Phase 2 Locally advanced	FFX + SBRT, 40 Gy (50)	1 year survival	15	11 to 18	1 year PFS	9	8 to 10	12.0‡

CRT=chemoradiotherapy; DFS=disease free survival; EFS=event free survival; FFX=folinic acid, fluorouracil, irinotecan hydrochloride, and oxaliplatin; Gem=gemcitabine; HR=hazard ratio; mFFX=modified FFX; NR=not reached; ORR=objective response rate; OS=overall survival; PFS=progression free survival; RO=margin negative; RCT=randomized controlled trial; RFS=recurrence free survival; RT=radiotherapy; SBRT=stereotactic body radiation therapy.

*The chemoradiotherapy group included patients who received chemoradiotherapy with or without chemotherapy (fluorouracil and folinic acid), and the no radiotherapy group included patients who received chemotherapy or observation only.

†Hazard ratio (95% confidence interval) of mortality is shown.

‡Resection rate (margin negative rate) is shown.

§Events were defined as disease progression, surgery with R2 resection, recurrent disease following surgery, or death from any cause.

¶Gemcitabine with or without erlotinib.

phase 2 study (LAPACT) investigated gemcitabine/nab-paclitaxel for 106 patients¹¹⁸; the median overall survival was 18.8 months (90% confidence interval 15.0 to 24.0 months). In total, 62 patients (58%) completed induction gemcitabine/nab-paclitaxel, and 17 patients (16%) underwent surgical resection. Another randomized phase 2 study (NEOLAP-AIO-PAK-0113) showed high surgical conversion rates of gemcitabine/nab-paclitaxel (23/64, 35.9%) and gemcitabine/nab-paclitaxel followed by FOLFIRINOX (29/66, 43.9%).¹¹⁹ No survival differences were observed between the two arms (hazard ratio 0.86; 95% confidence interval 0.55 to 1.36). These results suggest a new potential treatment strategy for surgical conversion of locally advanced disease, which could achieve longer survival in selected patients.

Surgical treatment

Pancreatectomy, especially pancreaticoduodenectomy, has been considered a high risk surgery. The centralization of pancreatectomy has played an essential role in the improvement of perioperative outcomes. The 90 day mortality is reported to be under 5-10% in experienced high volume centers.^{120 121} A recent meta-analysis including 46 retrospective studies (2015-2021) showed a significantly lower postoperative morbidity rate in high volume centers compared with low volume centers (47.1% v 56.2%; odds ratio 0.75; 95% confidence interval 0.65 to 0.88).¹²¹

Surgery for locally advanced and borderline disease

Some experts have pushed for more aggressive operations for patients with borderline resectable and locally advanced diseases with the advent of more effective systemic drugs. Resection after neoadjuvant treatment was reported to have

similar short term outcomes compared with upfront resection in a meta-analysis¹²² including randomized controlled trials and a subgroup report of a randomized phase 3 trial.¹²³ However, data on arterial resection and reconstruction are more controversial, and depend on the resected artery and the technical approach; the mortality rates were reported as 5.7% for resection of the superior mesenteric artery,¹²⁴ and 1.7% for resection of the celiac axis.¹²⁵ More recently, arterial divestment has been proposed as an alternative to arterial resection in selected patients. A retrospective study of a high volume center reported a mortality rate of 7.0% for arterial resections and 2.3% for arterial divestment from 2015 to 2019, although the breakdown of resected arteries was not shown by periods.¹²⁶ To be clear, these aggressive procedures should be performed only when long term survival is expected. A previous meta-analysis including 13 studies (2005-2015) with 355 locally advanced tumors showed no significant association between the resection rate after chemotherapy and overall survival.¹¹⁷ However, large, retrospective studies recently showed that conversion surgery for locally advanced diseases after FOLFIRINOX was associated with improved survival in a selected subgroup.^{127 128} Further studies are expected.

Surgery for patients with metastatic disease

Macroscopic distant metastasis is a contraindication to surgical resection in general. However, several studies have reported a potential role of resection in highly selected patients with limited metastatic diseases. A meta-analysis including three retrospective studies (2016-2019) showed a longer overall survival (23-56 months v 11-16 months) in patients with synchronous liver metastasis who underwent

Table 4 | Summary of studies on supportive/palliative care for pancreatic cancer

Study	Treatment	Aim	Results
NURIMAS Pancreas (2021) ¹⁶⁴ (n=116) Prospective	NA	To find a nutritional score that can identify patients with malnutrition related to worse survival after surgical resection	● Malnutrition classified by the Subjective Global Assessment score was associated with worse overall survival (HR 2.16; 95% CI 1.34 to 3.47)
Hamauchi et al (2019) ¹⁶⁵ (n=50) Prospective, single arm	Anamorelin, ¹⁶⁶ selective ghrelin receptor agonist, appetite enhancing, anabolic activity	To evaluate the efficacy and safety of anamorelin for patients with gastrointestinal cancers by the change of LBM (five patients had pancreatic cancer)	● The response rate was 63.3%, with an increase in LBM and body weight from baseline. The scores of appetite related questions showed improvements
Solheim et al (2017) ¹⁶⁷ (n=46) RCT, phase 2	Nutritional and exercise intervention* for cachexia	To assess the feasibility and efficacy of a multimodal intervention for cachexia in patients with advanced lung and pancreatic cancer	● 10 of 25 patients in the treatment arm and 10 of 21 patients in the control arm had pancreatic cancer ● The intervention was feasible and safe, but did not affect physical activity and muscle strength
Koulouris et al (2021) ¹⁶⁸ (n=727) Meta-analysis	EUS-CPN	To assess the efficacy of the EUS-CPN and to compare the differences in efficacy by technique	● Overall response rate was 68% (95% CI 61% to 74%) after two weeks and 53% (95% CI 45% to 62%) after four weeks ● No difference in the response rates between the three techniques
IMPERATIVE study (2023) ¹⁶⁹ (n=40) Case crossover study	Early palliative care†	To assess the effect of early palliative care (for 16 weeks) on QOL, symptom burden, anxiety, and depression	● Early palliative care was associated with the improvement of QOL and symptoms in patients with metastatic disease ● No difference in depression and anxiety

EUS-CPN=endoscopic ultrasound guided celiac plexus neurolysis; LBM=lean body mass; NA=not applicable; QOL=quality of life; HR=hazard ratio; RCT=randomized controlled trial.

*Intervention: celecoxib 300 mg once daily, nutrition with eicosapentaenoic acid 2 g per day, nutrition counseling, and exercise program.

†Technique: central injection, bilateral injection, and celiac ganglia neurolysis.

‡Palliative care: assessment, symptom management, discussion and education about the disease and goals of care, advance care planning, and follow-up assessment.

resection after chemotherapy (n=44) compared with those who did not (n=166).¹²⁹ In another review, lung metastasectomy was associated with a longer survival with a median overall survival after resection ranging from 18.6 to 38.3 months.¹³⁰ A large retrospective study suggested that only patients who achieved a complete pathological response of metastasis could

derive a survival benefit from resection.¹³¹ Further studies are expected to provide data on patient selection criteria and metastatic sites. A single arm phase 2 study (NCT04617457) and a randomized phase 3 trial (NCT03398291) are recruiting patients with oligometastasis in liver from pancreatic cancer to evaluate the efficacy of resection after chemotherapy.




Fig 2 | Precision medicine for pancreatic cancer. PanIN=pancreatic intraepithelial neoplasm

Minimally invasive surgery

Minimally invasive surgery for pancreatic cancer had until recently been lagging behind that for other cancers. Results of a recent randomized trial¹³² (n=656) and a meta-analysis of three randomized controlled trials¹³³ (n=224) showed that laparoscopic pancreatoduodenectomy was associated with a shorter hospital stay, but a similar postoperative morbidity rate. Box 3 summarizes the studies comparing robotic pancreatoduodenectomy with open or laparoscopic pancreatoduodenectomy. Notably, all studies on pancreatoduodenectomy to date have included patients with diseases other than pancreatic cancer. Another meta-analysis including 12 randomized or matched studies (n=4346) showed a similar morbidity rate, but a higher margin negative resection rate (odds ratio 1.46) and shorter time to adjuvant treatment, in the laparoscopic distal pancreatectomy group.¹³⁹ Most recently, an international randomized trial (DIPLOMA)¹⁴⁰ including 117 patients with resectable pancreatic cancer in the minimally invasive distal pancreatectomy group and 114 patients in the open distal pancreatectomy group showed the non-inferiority of the oncological safety of minimally invasive distal pancreatectomy: a higher margin negative resection rate (73% v 69%) and comparable lymph node yield and intraperitoneal recurrence.

Radiotherapy

Radiotherapy is used as a part of local treatment for pancreatic cancer, generally combined with chemotherapy. Since the gold standard for this disease remains surgical resection,⁶⁷ the role of radiotherapy has been logically examined in both the adjuvant setting and in locally advanced inoperable patients. The neoadjuvant application of radiotherapy has also been investigated in several studies. In this setting, however, high level evidence comparing the role of radiotherapy in a head-to-head design to neoadjuvant chemotherapy is lacking. The true efficacy of radiotherapy on long term survival remains unclear, especially when combined with modern multiagent systemic treatments and surgical resection. Another concern in many radiotherapy studies is the heterogeneity of the treatment technique and dose used. For example, the techniques have evolved from conventional treatments to intensity modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT), more ablative approaches with adaptive planning platforms. Box 4 summarizes the characteristics of radiotherapy by types and doses. Table 3 summarizes the clinical studies of radiotherapy.

Adjuvant radiotherapy

In theory, the purpose of adjuvant radiotherapy is to reduce the risk of local recurrence. NCCN guidelines recommend considering adjuvant chemoradiation treatment for patients with positive surgical margins.⁶⁷ However, prospective studies that support adjuvant radiotherapy are lacking, regardless of

the surgical margin status. The aforementioned large randomized phase 3 trial (ESPAC-1) included 289 resected patients: 51 (17.6%) had positive resection margins. The results showed worse survival in the chemoradiotherapy arm (n=145) than in the non-radiotherapy arm (n=144) (median overall survival 15.9 v 17.9 months; hazard ratio 1.28; 95% confidence interval 0.99 to 1.66).⁴ This study has discouraged further studies of adjuvant radiotherapy in Europe. However, the study had two major drawbacks. Firstly, the chemotherapy regimen was different in the chemotherapy arm (fluorouracil/leucovorin) and the chemoradiotherapy arm (fluorouracil). Secondly, the total dose of radiotherapy (20 Gy) did not reach 45 Gy, which represents the treatment dose of conventional, fractionated external beam radiotherapy.⁶⁷ Two randomized phase 2 studies investigated adjuvant gemcitabine plus radiotherapy for patients with negative resection margins. The first study administered 50.4 Gy in 28 fractions of radiotherapy, and found a lower local alone recurrence rate (11% v 24%), but did not show a difference in overall survival or disease free survival between the two arms (45 patients each).¹⁴³ The other small study (n=38) used a modern SBRT technique (25 Gy in five fractions), but showed no difference in any of the survival endpoints (recurrence free survival, locoregional recurrence free survival, or overall survival), even in the node positive subgroup.¹⁴⁴ An older systematic review included five randomized controlled trials (1985-2005) of adjuvant chemoradiotherapy consisting of fluorouracil based chemotherapy plus conventional radiotherapy, and showed no survival benefit of chemoradiation (pooled hazard ratio 1.09; 95% confidence interval 0.89 to 1.32).¹⁴⁵ The subgroup analysis in this study showed a possible efficacy of adjuvant chemoradiotherapy in patients with positive resection margins.

The RTOG0848 trial is a randomized phase 2/3 study that enrolled 322 resected patients. The ongoing phase 3 of this trial assesses the survival benefit of added radiotherapy (50.4 Gy) after six cycles of adjuvant gemcitabine based chemotherapy. However, because the standard of care regimen of adjuvant chemotherapy has changed to FOLFIRINOX, the results of this study might have a limited impact on clinical practice. Ultimately, the role of adjuvant radiotherapy is still ambiguous.

Neoadjuvant radiotherapy

One of the primary goals of neoadjuvant radiotherapy is to reduce the rate of positive margin resection, which is a risk factor for local recurrence. Two single arm phase 2 studies showed the tolerability and feasibility of concurrent radiotherapy combined with fluorouracil plus cisplatin¹⁴⁶ (n=41) and gemcitabine (n=41).¹⁴⁷ However, the evidence on the efficacy of neoadjuvant radiotherapy is inconsistent. A meta-analysis of three randomized controlled trials (n=189) that investigated chemoradiotherapy (fluorouracil based chemotherapy with a radiotherapy dose of

45-50.4 Gy) did not show any difference in overall survival between neoadjuvant chemoradiotherapy and adjuvant chemoradiotherapy (hazard ratio 0.93; 95% confidence interval 0.69 to 1.25).¹⁴⁸ The aforementioned PREOPANC-1 phase 3 trial, which showed a survival benefit of neoadjuvant chemoradiotherapy for borderline resectable disease, did not evaluate effects with and without radiation.¹¹⁰ Regarding neoadjuvant chemoradiotherapy with FOLFIRINOX, a phase 2 trial (n=48) showed that neoadjuvant FOLFIRINOX plus chemoradiotherapy in borderline resectable disease showed a high rate of margin negative resection, and prolonged median progression free survival and even median overall survival.¹⁴⁹ By contrast, a randomized phase 2 trial (ALLIANCE-A021501) showed worse survival in the patients with borderline resectable disease who were allocated to the neoadjuvant mFOLFIRINOX plus radiotherapy (SBRT or hypofractionated image guided radiotherapy) arm (n=56) compared with those who allocated to the neoadjuvant mFOLFIRINOX alone arm (n=70) (median overall survival 17.1 v 29.8 months; median event free survival 10.2 v 15.0 months).¹⁵⁰ However, the number of patients was modest, and the dropout rates were high in both the chemotherapy arm (71.4%) and the chemoradiation arm (82.1%). A meta-analysis comprising 15 studies (512 patients) of neoadjuvant FOLFIRINOX with or without radiotherapy for resectable and borderline resectable disease showed a better rate of margin negative resection in the chemoradiotherapy group (97.6% v 88.0%).¹⁵¹ No differences were observed in resection rate, overall survival, or pathological outcomes. The PANDAS-PRODIGE 44 study, a randomized phase 2 study, assigned 130 patients with borderline resectable diseases to mFOLFIRINOX or mFOLFIRINOX plus conformal external radiation (50.4 Gy). This ongoing study aims to evaluate the histological negative margin resection rate as the primary endpoint.

Radiation for locally advanced disease

For locally advanced pancreatic cancer, radiation is used as the primary modality for local control and, on rare occasions, to facilitate margin negative resection in select patients who achieve good responses to treatment.⁶⁷ Trials for locally advanced diseases have reported various levels of efficacy. A randomized trial assigned 37 patients to receive chemoradiotherapy (gemcitabine, 50.4 Gy) and 34 patients to receive gemcitabine alone. The trial showed improved overall survival in the chemoradiotherapy group (11.1 v 9.2 months).¹⁵² Progression free survival was not different, but the sample size was notably small. The LAP07 trial was a large randomized phase 3 trial that aimed to investigate the survival benefit of adding radiotherapy to chemotherapy (54 Gy plus capecitabine) compared with chemotherapy (gemcitabine or gemcitabine plus erlotinib) after four months of gemcitabine based induction chemotherapy.¹⁵³ The results showed no differences in overall (median 15.2 v 16.5 months; hazard ratio

1.03; 95% confidence interval 0.79 to 1.34) or progression free survival (9.9 v 8.4 months; 0.78; 0.61 to 1.01) between the chemoradiotherapy group (n=133) and the chemotherapy group (n=136). An older randomized phase 3 trial (2000-01 FFCD/SFRO) also compared gemcitabine chemotherapy (n=60) to chemoradiotherapy with fluorouracil and cisplatin (60 Gy) (n=59),¹⁵⁴ and showed worse overall survival (median 8.6 v 13.0 months) and progression free survival in the chemoradiotherapy group.¹⁵⁴ The study, however, suffered from major inconsistencies in the proportion of patients who received at least 75% of the planned dose of induction chemotherapy, being only 42.4% in the chemoradiotherapy group compared with 73.3% in the chemotherapy group.

Given that conventional fractionated radiotherapy techniques combined with gemcitabine based chemotherapy have failed to show a significant survival advantage, the focus of research has moved to SBRT and FOLFIRINOX. A meta-analysis of 1147 patients from 21 studies including randomized controlled trials (2002-2014) compared conventional external beam techniques to SBRT.¹⁴¹ The estimated two year overall survival was higher in the SBRT group (26.9% v 13.7%), with less acute grade 3/4 toxicity (5.6% v 37.7%) and similar late grade 3/4 toxicity (9.0% v 10.1%). A phase 2 trial (LAPC-1) enrolled 50 patients to receive eight cycles of FOLFIRINOX followed by SBRT (40 Gy in five fractions).¹⁵⁵ In total, 39 patients underwent SBRT (78.0%) and seven (14.0%) patients underwent surgical resection; all had negative margins and pathological N0 stage. The overall survival in the resected patients was longer than in the unresected patients (median 24 v 15 months; three year survival rate 43% v 6.5%). A systematic review including 2446 patients from 28 phase 2/3 studies also showed a similar resection rate of 12.1% (95% confidence interval 10.0% to 14.5%). Therefore, this newest chemoradiotherapy approach could give the best chance of curative intent surgery, and achieve long term survival in a highly selected subgroup of patients.

Four phase 2/3 trials are ongoing. The CONKO-007 trial is a large randomized phase 3 trial enrolling 525 patients to evaluate chemoradiotherapy (50.4 Gy with gemcitabine) after induction chemotherapy with FOLFIRINOX (n=402) or gemcitabine (n=93) for three months; the primary endpoint was margin negative resection rate. The first results came out in 2022, and showed a higher rate of margin negative resection (resection and circumferential resection margin) (9.0% v 19.6%) in the chemoradiation arm (n=168, 61 underwent surgery) compared with the chemotherapy arm, which was continuing FOLFIRINOX or gemcitabine (n=167, 60 underwent surgery).¹⁵⁶ However, the total surgical resection margin negativity rate and survival did not reach statistical significance. The publication is pending. The other three trials are phase 2 trials and are still recruiting patients (SCALOP-2,¹⁵⁷ MASTERPLAN,¹⁵⁸ and GABRINOX-ART¹⁵⁹). These studies could provide more data about gemcitabine/nab-paclitaxel and

SBRT for locally advanced pancreatic cancer. However, we are unable to draw a conclusion without well designed phase 3 trials using the latest technology and chemotherapy regimen.

Supportive care and palliative care

Weight loss is seen in more than half of patients at diagnosis of pancreatic cancer¹¹; as a result, the rates of malnutrition^{160,161} (33.7-70.6%) and sarcopenia¹⁶² (up to 74%) are high. Malnutrition and sarcopenia have been reported to be associated with poor outcomes of surgical resection and chemotherapy.¹⁶³ Given that the majority of patients suffer from metastatic diseases, palliative care, including pain management and nutrition support, is essential to their quality of life, and even prognosis. Table 4 highlights major studies on these topics.

Emerging diagnostic tools and treatments

Diagnostic tools

Fibrosis, both chemoradiotherapy induced and cancer associated, has been reported to be associated with overall survival. An MRI probe targeting chemoradiotherapy induced collagen (type I collagen) can detect this change in fibrosis.¹⁷⁰ Radiolabeled fibroblast activation protein inhibitors (FAPI) can target the expression of fibroblast activation protein in cancer associated fibroblasts, which is abundant in pancreatic cancer.¹⁷¹ A meta-analysis showed superior performance of FAPI PET over FDG PET/CT/MRI for the determination of tumor, node, metastases (TNM) classification and peritoneal carcinomatosis.¹⁷² A phase 2 trial is recruiting patients to evaluate the efficacy of FAPI PET/CT in patients with locally advanced disease (NCT05518903).

Radiomics using machine learning or deep learning (artificial intelligence) is a new field of research, driven by advances in computer systems. Theoretically, a computer can learn and identify features and differences that a human cannot. A systematic review showed that radiomics models of the primary tumors had good performance in predicting patient prognosis.¹⁷³ Further studies with larger sample sizes for training and validating models with risk factors, images, and biomarkers will yield more conclusive results in this regard.

Systemic treatment

In the era of neoadjuvant chemotherapy, a new question has emerged of how to manage patients who have tumor progression during neoadjuvant treatment. A phase 2 trial (NCT03322995) is recruiting patients (n=125) with resectable and borderline resectable disease to evaluate the efficacy of adaptive modification of neoadjuvant treatment (four months). Based on the results of restaging after four cycles of FOLFIRINOX, a decision will be made to either continue the same regimen, or switch to a gemcitabine based regimen and chemoradiotherapy. For locally advanced pancreatic cancer, the NEOPAN phase 3 trial successfully enrolled 171 patients with

locally advanced pancreatic cancer to compare the progression free survival of FOLFIRINOX (12 cycles) with gemcitabine (four cycles), with preliminary results expected soon. Few data exist on the comparison of FOLFIRINOX with gemcitabine/nab-paclitaxel for both localized and advanced cancer. A randomized phase 2 study (PASS-01) is recruiting patients (planned n=150) with metastatic disease to investigate the difference in progression free survival between the two regimens. Moreover, genomic factors and putative biomarkers will be explored using whole genome sequencing and RNA sequencing, and patient derived organoids.

Immunotherapy has been largely ineffective in pancreatic cancer, potentially owing to both tumor cell intrinsic and tumor microenvironment factors. Recent trials have taken a combined approach. CISP3, a randomized phase 3 trial (n=110), showed an improved objective response rate (50.0% v 23.9%; P=0.010) by adding sintilimab (a monoclonal antibody against programmed cell death protein 1) to FOLFIRINOX for metastatic patients,¹⁷⁴ albeit without superior overall survival and progression free survival. The same group is conducting a phase 3 trial to evaluate the same regimen in patients with borderline resectable and locally advanced diseases (NCT03983057). Given the results of basic research in pancreatic cancer showing that the extracellular matrix plays an essential role in the tumor microenvironment and progression, several new agents have been introduced. A phase 2 trial (NCT03336216) combining an immune checkpoint inhibitor with chemotherapy (FOLFIRINOX or gemcitabine based regimen) and cabiralizumab (a colony stimulating factor 1 receptor inhibitor that suppresses the activities of tumor associated macrophages) has been conducted. However, a 2020 press release^{175,176} announced that this study missed the primary endpoint of progression free survival.

Pamrevlumab, a recombinant human monoclonal antibody against connective tissue growth factor, has been investigated in a randomized phase 3 trial (LAPIS) combined with FOLFIRINOX or gemcitabine/nab-paclitaxel (up to six cycles) for locally advanced tumors. The study has completed recruitment (n=284) and is continuing to evaluate the primary endpoint of overall survival. Most recently, a phase 1 trial proposed a notable approach to stimulating cancer immunity in pancreatic cancer, with promising results.¹⁷⁷ The study adopted the messenger RNA (mRNA) vaccine technique to make a personalized mRNA vaccine encoding five or more neoantigens, which were bioinformatically predicted from the resected primary tumor. This adjuvant treatment consisted of one dose of atezolizumab (anti-PDL1 (programmed death ligand 1) antibody) and eight doses (one week) of mRNA neoantigen vaccines, followed by 12 cycles of mFOLFIRINOX. In total, 16 of 28 resected patients received personalized vaccines, and eight patients responded to the vaccines, with no recurrence among responders after a median follow-up of 18.0 months. Larger studies will help establish

whether this is a breakthrough in immunotherapy for pancreatic cancer.

Treatment strategies targeting specific genomic alterations have been explored in various molecularly defined patient subsets. Given the positive results for metastatic cancer in the POLO trial,⁹³ olaparib is being studied in a randomized phase 2 trial (APOLLO) to evaluate the additional benefit of one year of treatment on recurrence free survival in patients with a pathogenic BRCA1, BRCA2, or PALB2 mutation, who have received at least three months of multi-agent chemotherapy after curative resection. KRAS is an attractive target owing to its high rate of mutation (90%) in pancreatic cancer.¹⁷⁸ Although KRAS G12C mutations are rare (1.6% of pancreatic ductal adenocarcinoma (PDAC) cases), the ability to create covalent G12C inhibitors led to FDA approval in non-small cell lung cancer, and promising initial results in PDAC. Sotorasib, a KRAS G12C inhibitor, showed a median progression free survival of four months, and an objective response rate of 21% in metastatic patients with KRAS G12C mutations who received at least two lines of chemotherapy in a phase 1/2 trial.¹⁷⁹ Another KRAS G12C inhibitor, adagrasib, showed a median progression free survival of 6.6 months, and an objective response rate of 50% (5/10 patients), in patients with advanced pancreatic cancer in a phase 1/2 trial (KRYSTAL).¹⁸⁰

By contrast to the low mutation rate in BRCA1 (1.08%), BRCA2 (1.48%), PALB2 (0.54%), and KRAS G12C (1-2%), other KRAS mutations are quite common, and pan-KRAS inhibitors are under investigation. Two phase 1 studies of pan-RAS inhibitors are recruiting patients (NCT04678648 and NCT05379985). Further studies on other KRAS targeting approaches are expected.

Radiotherapy

Radiotherapy has been suggested to have synergistic effects on local and even distant tumors when combined with immunotherapy.^{181 182} A large randomized phase 3 trial showed that chemoradiotherapy followed by durvalumab (PDL1 inhibitor) had significantly longer overall survival than placebo in locally advanced, non-small cell lung cancer.¹⁸³ Recently, a phase 2 trial (CheckPAC) assigned 84 patients with refractory metastatic pancreatic cancer to receive SBRT/nivolumab (n=41) or SBRT/nivolumab/ipilimumab (n=43).¹⁸⁴ The SBRT/nivolumab/ipilimumab arm had a higher disease control rate (37.2% v 17.1%). Further studies with an immunotherapy-SBRT backbone are anticipated in locally advanced and metastatic disease settings.

Figure 2 summarizes all the data discussed above, and gives perspective on the future of the management of pancreatic cancer.

Guidelines

Several national and international guidelines for the management of pancreatic cancer have been published. Recommendations of those guidelines are proposed considering the evidence and the

healthcare system of each country. We reviewed two major guidelines of the US and Europe, and also included the recent 2022 updated Japanese guideline.⁶⁻⁸ All recommendations of these guidelines are made based on the metastatic status and the anatomical resectability of the primary tumors. Regarding treatments for resectable diseases, the NCCN guidelines list neoadjuvant chemotherapy as an option for high risk patients, and the Japan Pancreas Society guidelines recommend neoadjuvant for all patients. The ESMO guidelines recommend only upfront surgery. The NCCN and ESMO guidelines recommend mFOLFIRINOX as the first option of adjuvant chemotherapy, although S-1 monotherapy is recommended by the Japan Pancreas Society guidelines. Conversion surgery for locally advanced disease is an option in the NCCN and Japan Pancreas Society guidelines. No recommendation is made for conversion surgery for metastatic disease in any of the three sets of guidelines. Radiotherapy is listed as an option for non-metastatic diseases in the NCCN guidelines, while the other guidelines do not recommend it for resectable diseases. The NCCN

RESEARCH QUESTIONS

- In patients treated with upfront systemic treatment, what is the optimal duration of systemic treatment and patient selection for surgical resection?
- How can immuno-oncology and targeted treatment be made effective?
- What is the optimal combination and sequence of radiotherapy, and who are the ideal targets?
- What is the specific population that needs routine screening and what is an effective combination of tests to detect precancerous lesions?

GLOSSARY OF ABBREVIATIONS

- NCCN: National Comprehensive Cancer Network
- ESMO: European Society for Medical Oncology
- PanIN: pancreatic intraepithelial neoplasia
- IPMN: intraductal papillary mucinous neoplasm
- CAPS: International Cancer of the Pancreas Screening
- USPSTF: United States Preventive Services Task Force
- CA19-9: carbohydrate antigen 19-9
- RECIST: response evaluation criteria in solid tumors
- FOLFIRINOX: combined leucovorin calcium (folinic acid), fluorouracil, irinotecan, and oxaliplatin
- NALIRIFOX: combined liposomal irinotecan, fluorouracil, folinic acid, and oxaliplatin
- mFOLFIRINOX: modified FOLFIRINOX
- PEFG regimen: cisplatin, epirubicin, fluorouracil, and gemcitabine
- IMRT: intensity modulated radiation therapy
- SBRT: stereotactic body radiation therapy
- 3D-CRT: 3 dimensional conformal radiation therapy
- IGRT: image guided radiation therapy
- FAPI: fibroblast activation protein inhibitors
- PDAC: pancreatic ductal adenocarcinoma
- PDL1: programmed death ligand 1

guidelines recommend genetic testing of inherited mutations for all patients with pancreatic cancer, but no clear recommendations are made in the other sets of guidelines.

Conclusions

In the US and Europe, the incidence of pancreatic cancer has been increasing consistently, and this trend is estimated to continue for several decades. Advances in the combination of cytotoxic drugs have resulted in improvements in survival for all stages of the disease, and are changing treatment algorithms. Further investigation into the role of immunology agents and radiation could help a subset of patients. In addition, extensive efforts need to focus on risk assessment, screening, and early detection.

Competing interests: We have read and understood the BMJ policy on declaration of interests and declare the following interests: MDC receives grants from Haemonetics, and is the primary investigator of a Boston Scientific sponsored study. TS does not have conflicts of interest to declare. SDK receives investigator initiated clinical trial funding from Genentech and AstraZeneca. She also receives preclinical research support from Roche and Amgen. WAM receives institutional clinical trial funding from Genentech, Beigene, Pfizer, NGM, Gossamer, ALX, Exelixis, EDDC/D3, Mirati, RasCal Therapeutics, and CanBAS. He is also a Data and Safety Monitoring Board member of QED, Amgen, and Zymeworks.

Funding: This study is supported by funding sources: R01 DE028529-01 (SDK), R01 DE028282-01 (SDK), 1R01CA284651-01 (SDK), 1P50CA261605-01 (SDK), and the V Foundation Translational Research Award. The funders had no role in considering the study design or in the collection, interpretation of data, writing of the manuscript, or decision to submit the article for publication.

Contributors: Authors MDC and TS are joint first authors. The design, literature search, review, and writing of this manuscript was led by MDC and TS, and supported by SDK and WAM. MDC is the guarantor. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

We thank Hiroyuki Ishida for his drawings in figure 2, and Michael J Kirsch for his assistance in proofreading this manuscript.

Patient involvement: No patients were involved in the writing of this review.

Provenance and peer review: commissioned; externally peer reviewed.

- Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? *JAMA* 2000;283:2975-8. doi:10.1001/jama.283.22.2975.
- Bengtsson A, Andersson R, Ansari D. The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data. *Sci Rep* 2020;10:16425. doi:10.1038/s41598-020-73525-y.
- Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. *CA Cancer J Clin* 2023;73:17-48. doi:10.3322/caac.21763.
- Neoptolemos JP, Stocken DD, Friess H, et al. European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. *N Engl J Med* 2004;350:1200-10. doi:10.1056/NEJMoa032295.
- Conroy T, Hammel P, Hebbar M, et al. Canadian Cancer Trials Group and the Unicancer-GI-PRODIGE Group. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. *N Engl J Med* 2018;379:2395-406. doi:10.1056/NEJMoa1809775.
- National Comprehensive Cancer Network. Pancreatic Adenocarcinoma (Version 2.2022)
- Ducruex M, Cuhna AS, Caramella C, et al. ESMO Guidelines Committee. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2015;26(Suppl 5):v56-68. doi:10.1093/annonc/mdv295.
- Okusaka T, Nakamura M, Yoshida M, et al. Committee for Revision of Clinical Guidelines for Pancreatic Cancer of the Japan Pancreas Society. Clinical practice guidelines for pancreatic cancer 2022 from the Japan pancreas society: a synopsis. *Int J Clin Oncol* 2023;28:493-511. doi:10.1007/s10147-023-02317-x.
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2021;71:209-49. doi:10.3322/caac.21660.
- Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US cancer incidence and death to 2040. *JAMA Netw Open* 2021;4:e214708. doi:10.1001/jamanetworkopen.2021.4708.
- Walter FM, Mills K, Mendonça SC, et al. Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study. *Lancet Gastroenterol Hepatol* 2016;1:298-306. doi:10.1016/S2468-1253(16)30079-6.
- Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. *Cancer Res* 2004;64:2634-8. doi:10.1158/0008-5472.CAN-03-3823.
- Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. *Gastroenterology* 2000;119:1447-53. doi:10.1053/gast.2000.20228.
- Vasen HF, Gruis NA, Frants RR, van Der Velden PA, Hille ET, Bergman W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). *Int J Cancer* 2000;87:809-11. doi:10.1002/1097-0215(20000915)87:6<809::AID-IJCC>3.0.CO;2-U
- Vasen HF, Boutron-Ruault MC, Schnee M, et al. Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. *Am J Gastroenterol* 2008;103:111-9. doi:10.1111/j.1572-0241.2007.01597.x.
- Lynch HT, Deters CA, Snyder CL, et al. BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. *Cancer Genet Cytogenet* 2005;158:119-25. doi:10.1016/j.cancergencyto.2004.01.032.
- Kastrinos F, Mukherjee B, Tayob N, et al. Risk of pancreatic cancer in families with Lynch syndrome. *JAMA* 2009;302:1790-5. doi:10.1001/jama.2009.1529.
- Lugo A, Peveri G, Bosetti C, et al. Strong excess risk of pancreatic cancer for low frequency and duration of cigarette smoking: A comprehensive review and meta-analysis. *Eur J Cancer* 2018;104:117-26. doi:10.1016/j.ejca.2018.09.007.
- Aune D, Greenwood DC, Chan DS, et al. Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies. *Ann Oncol* 2012;23:843-52. doi:10.1093/annonc/mdr398.
- Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. *Eur J Cancer* 2011;47:1928-37. doi:10.1016/j.ejca.2011.03.003.
- Kirkegård J, Mortensen FV, Cronin-Fenton D. Chronic pancreatitis and pancreatic cancer risk: a systematic review and meta-analysis. *Am J Gastroenterol* 2017;112:1366-72. doi:10.1038/ajg.2017.218.
- Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. *Lancet Oncol* 2009;10:88-95. doi:10.1016/S1470-2045(08)70337-1.
- Chari ST, Maitra A, Matrisian LM, et al. Early Detection Initiative Consortium. Early Detection Initiative: A randomized controlled trial of algorithm-based screening in patients with new onset hyperglycemia and diabetes for early detection of pancreatic ductal adenocarcinoma. *Contemp Clin Trials* 2022;113:106659. doi:10.1016/j.cct.2021.106659.
- Notta F, Chan-Seng-Yue M, Lemire M, et al. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. *Nature* 2016;538:378-82. doi:10.1038/nature19823.
- Dbouk M, Katona BW, Brand RE, et al. The multicenter cancer of pancreas screening study: impact on stage and survival. *J Clin Oncol* 2022;40:3257-66. doi:10.1200/JCO.22.00298.
- Balduzzi A, Marchegiani G, Pollini T, et al. Systematic review and meta-analysis of observational studies on BD-IPMNS progression to malignancy. *Pancreatol* 2021;21:1135-45. doi:10.1016/j.pan.2021.04.009.
- Wu YHA, Oba A, Beaty L, et al. Ductal dilatation of ≥5 mm in intraductal papillary mucinous neoplasm should trigger the consideration for pancreatectomy: a meta-analysis and systematic review of resected cases. *Cancers (Basel)* 2021;13:2031. doi:10.3390/cancers13092031.
- Goggins M, Overbeek KA, Brand R, et al. International Cancer of the Pancreas Screening (CAPS) consortium. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. *Gut* 2020;69:7-17. doi:10.1136/gutjnl-2019-319352.
- Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. *Nature* 2010;467:1114-7. doi:10.1038/nature09515.
- Gerstung M, Jolly C, Leshchiner I, et al. PCAWG Evolution & Heterogeneity Working Group/PCAWG Consortium. The evolutionary history of 2,658 cancers. *Nature* 2020;578:122-8. doi:10.1038/s41586-019-1907-7.

- 31 Noë M, Niknafs N, Fischer CG, et al. Genomic characterization of malignant progression in neoplastic pancreatic cysts. *Nat Commun* 2020;11:4085. doi:10.1038/s41467-020-17917-8.
- 32 Overbeek KA, Goggins MG, Dbouk M, et al, International Cancer of the Pancreas Screening Consortium. Timeline of development of pancreatic cancer and implications for successful early detection in high-risk individuals. *Gastroenterology* 2022;162:772-785.e4. doi:10.1053/j.gastro.2021.10.014.
- 33 Tjaden C, Sandini M, Mihaljevic AL, et al. Risk of the watch-and-wait concept in surgical treatment of intraductal papillary mucinous neoplasm. *JAMA Surg* 2021;156:818-25. doi:10.1001/jamasurg.2021.0950.
- 34 Tanaka M, Fernández-Del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. *Pancreatol* 2017;17:738-53. doi:10.1016/j.pan.2017.07.007.
- 35 European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. *Gut* 2018;67:789-804. doi:10.1136/gutjnl-2018-316027.
- 36 Owens DK, Davidson KW, Krist AH, et al, US Preventive Services Task Force. Screening for pancreatic cancer. *JAMA* 2019;322:438-44. doi:10.1001/jama.2019.10232.
- 37 Steinberg WM, Gelfand R, Anderson KK, et al. Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. *Gastroenterology* 1986;90:343-9. doi:10.1016/0016-5085(86)90930-3.
- 38 Fahrman JF, Schmidt CM, Mao X, et al. Lead-time trajectory of CA19-9 as an anchor marker for pancreatic cancer early detection. *Gastroenterology* 2021;160:1373-1383.e6. doi:10.1053/j.gastro.2020.11.052.
- 39 Tanaka M, Mihaljevic AL, Probst P, et al. Meta-analysis of recurrence pattern after resection for pancreatic cancer. *Br J Surg* 2019;106:1590-601. doi:10.1002/bjs.11295.
- 40 Visser IJ, Levink IJM, Peppelenbosch MP, Fuhler GM, Bruno MJ, Cahen DL. Systematic review and meta-analysis: Diagnostic performance of DNA alterations in pancreatic juice for the detection of pancreatic cancer. *Pancreatol* 2022;22:973-86. doi:10.1016/j.pan.2022.06.260.
- 41 Pang TCY, Po JW, Becker TM, et al. Circulating tumour cells in pancreatic cancer: A systematic review and meta-analysis of clinicopathological implications. *Pancreatol* 2021;21:103-14. doi:10.1016/j.pan.2020.11.022.
- 42 Guven DC, Sahin TK, Yildirim HC, Aktepe OH, Dizdar O, Yalcin S. A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer. *Crit Rev Oncol Hematol* 2021;168:103528. doi:10.1016/j.critrevonc.2021.103528.
- 43 Lee J-S, Rhee T-M, Pietrasz D, et al. Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. *Sci Rep* 2019;9:16971. doi:10.1038/s41598-019-53271-6.
- 44 Khan IA, Saraya A. Circulating micromas as noninvasive diagnostic and prognostic biomarkers in pancreatic cancer: a review. *J Gastrointest Cancer* 2023;54:720-30. doi:10.1007/s12029-022-00877-1.
- 45 Bunduc S, Gede N, Vancsa S, et al. Exosomes as prognostic biomarkers in pancreatic ductal adenocarcinoma—a systematic review and meta-analysis. *Transl Res* 2022;244:126-36. doi:10.1016/j.trsl.2022.01.001.
- 46 Li Y, Fan Z, Meng Y, Liu S, Zhan H. Blood-based DNA methylation signatures in cancer: A systematic review. *Biochim Biophys Acta Mol Basis Dis* 2023;1869:166583. doi:10.1016/j.bbdis.2022.166583.
- 47 Toft J, Hadden WJ, Laurence JM, et al. Imaging modalities in the diagnosis of pancreatic adenocarcinoma: A systematic review and meta-analysis of sensitivity, specificity and diagnostic accuracy. *Eur J Radiol* 2017;92:17-23. doi:10.1016/j.ejrad.2017.04.009.
- 48 Krishna SG, Rao BB, Ugarbugba E, et al. Diagnostic performance of endoscopic ultrasound for detection of pancreatic malignancy following an indeterminate multidetector CT scan: a systemic review and meta-analysis. *Surg Endosc* 2017;31:4558-67. doi:10.1007/s00464-017-5516-y.
- 49 Boyd LNC, Ali M, Leeflang MMG, et al. Diagnostic accuracy and added value of blood-based protein biomarkers for pancreatic cancer: A meta-analysis of aggregate and individual participant data. *EClinicalMedicine* 2022;55:101747. doi:10.1016/j.eclinm.2022.101747.
- 50 Zhang Y, Huang J, Chen M, Jiao LR. Preoperative vascular evaluation with computed tomography and magnetic resonance imaging for pancreatic cancer: a meta-analysis. *Pancreatol* 2012;12:227-33. doi:10.1016/j.pan.2012.03.057.
- 51 Treadwell JR, Zafar HM, Mitchell MD, Tipton K, Teitelbaum U, Jue J. Imaging tests for the diagnosis and staging of pancreatic adenocarcinoma: a meta-analysis. *Pancreas* 2016;45:789-95. doi:10.1097/MPA.0000000000000524.
- 52 Yang R, Lu M, Qian X, et al. Diagnostic accuracy of EUS and CT of vascular invasion in pancreatic cancer: a systematic review. *J Cancer Res Clin Oncol* 2014;140:2077-86. doi:10.1007/s00432-014-1728-x.
- 53 Park S, Jang JK, Byun JH, et al. CT in the prediction of margin-negative resection in pancreatic cancer following neoadjuvant treatment: a systematic review and meta-analysis. *Eur Radiol* 2021;31:3383-93. doi:10.1007/s00330-020-07433-0.
- 54 Dalah E, Erickson B, Oshima K, et al. Correlation of ADC with pathological treatment response for radiation therapy of pancreatic cancer. *Transl Oncol* 2018;11:391-8. doi:10.1016/j.tranon.2018.01.018.
- 55 Kang JH, Lee SS, Kim JH, et al. Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer. *Eur Radiol* 2021;31:864-74. doi:10.1007/s00330-020-07134-8.
- 56 Evangelista L, Zucchetto P, Moletta L, et al. The role of FDG PET/CT or PET/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: a systematic literature review. *Ann Nucl Med* 2021;35:767-76. doi:10.1007/s12149-021-01629-0.
- 57 Janssen BV, van Roessel S, van Dieren S, et al, International Study Group of Pancreatic Pathologists (ISGPP). Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). *Br J Surg* 2022;110:67-75. doi:10.1093/bjs/znac350.
- 58 Ye C, Sadula A, Ren S, et al. The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis. *Cancer Chemother Pharmacol* 2020;86:731-40. doi:10.1007/s00280-020-04165-2.
- 59 Kim SS, Lee S, Lee HS, Bang S, Han K, Park MS. Retrospective evaluation of treatment response in patients with nonmetastatic pancreatic cancer using CT and CA 19-9. *Radiology* 2022;303:548-56. doi:10.1148/radiol.212236.
- 60 Tie J, Cohen JD, Lahouel K, et al, DYNAMIC Investigators. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. *N Engl J Med* 2022;386:2261-72. doi:10.1056/NEJMoa2200075.
- 61 Raphael BJ, Hruban RH, Aguirre AJ, et al, Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. *Cancer Cell* 2017;32:185-203.e13. doi:10.1016/j.ccell.2017.07.007.
- 62 Moffitt RA, Marayati R, Flate EL, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. *Nat Genet* 2015;47:1168-78. doi:10.1038/ng.3398.
- 63 Aung KL, Fischer SE, Denroche RE, et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. *Clin Cancer Res* 2018;24:1344-54. doi:10.1158/1078-0432.CCR-17-2994.
- 64 Chan-Seng-Yue M, Kim JC, Wilson GW, et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. *Nat Genet* 2020;52:231-40. doi:10.1038/s41588-019-0566-9.
- 65 Hynes RO. The extracellular matrix: not just pretty fibrils. *Science* 2009;326:1216-9. doi:10.1126/science.1176009.
- 66 Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. *Ann Surg Oncol* 2009;16:1727-33. doi:10.1245/s10434-009-0408-6.
- 67 National Comprehensive Cancer Network. Pancreatic Adenocarcinoma (Version 2.2022). https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf
- 68 Burris HA3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol* 1997;15:2403-13. doi:10.1200/JCO.1997.15.6.2403.
- 69 Moore MJ, Goldstein D, Hamm J, et al, National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 2007;25:1960-6. doi:10.1200/JCO.2006.07.9525.
- 70 Reni M, Cordio S, Milandri C, et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. *Lancet Oncol* 2005;6:369-76. doi:10.1016/S1470-2045(05)70175-3.
- 71 Conroy T, Desseigne F, Ychou M, et al, Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med* 2011;364:1817-25. doi:10.1056/NEJMoa1011923.
- 72 Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. *J Clin Oncol* 2002;20:3270-5. doi:10.1200/JCO.2002.11.149.

- 73 Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. *J Clin Oncol* 2004;22:3776-83. doi:10.1200/JCO.2004.12.082.
- 74 Louvet C, Labianca R, Hammel P, et al. GERCOR, GISCAD. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. *J Clin Oncol* 2005;23:3509-16. doi:10.1200/JCO.2005.06.023.
- 75 Poplin E, Feng Y, Berlin J, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. *J Clin Oncol* 2009;27:3778-85. doi:10.1200/JCO.2008.20.9007.
- 76 Heinemann V, Quitzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. *J Clin Oncol* 2006;24:3946-52. doi:10.1200/JCO.2005.05.1490.
- 77 Colucci G, Labianca R, Di Costanzo F, et al. Gruppo Oncologico Italia Meridionale (GOIM), Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD), Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. *J Clin Oncol* 2010;28:1645-51. doi:10.1200/JCO.2009.25.4433.
- 78 Herrmann R, Bodoky G, Ruhstaller T, et al. Swiss Group for Clinical Cancer Research, Central European Cooperative Oncology Group. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. *J Clin Oncol* 2007;25:2212-7. doi:10.1200/JCO.2006.09.0886.
- 79 Bernhard J, Dietrich D, Scheithauer W, et al. Central European Cooperative Oncology Group. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial-SAKK 44/00-CECOG/PAN.1.3.001. *J Clin Oncol* 2008;26:3695-701. doi:10.1200/JCO.2007.15.6240.
- 80 Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. *J Clin Oncol* 2009;27:5513-8. doi:10.1200/JCO.2009.24.2446.
- 81 Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. *J Clin Oncol* 2004;22:1430-8. doi:10.1200/JCO.2004.10.112.
- 82 Cascinu S, Berardi R, Labianca R, et al. Italian Group for the Study of Digestive Tract Cancer (GISCAD). Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. *Lancet Oncol* 2008;9:39-44. doi:10.1016/S1470-2045(07)70383-2.
- 83 Van Cutsem E, Vermeulen WL, Bannoun J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. *J Clin Oncol* 2009;27:2231-7. doi:10.1200/JCO.2008.20.0238.
- 84 Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). *J Clin Oncol* 2010;28:3617-22. doi:10.1200/JCO.2010.28.1386.
- 85 Kindler HL, Ioka T, Richel DJ, et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. *Lancet Oncol* 2011;12:256-62. doi:10.1016/S1470-2045(11)70004-3.
- 86 Middleton G, Palmer DH, Greenhalf W, et al. Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (VIP): a prospective, randomised, double-blind, multicentre phase 2 trial. *Lancet Oncol* 2017;18:486-99. doi:10.1016/S1470-2045(17)30084-0.
- 87 Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med* 2013;369:1691-703. doi:10.1056/NEJMoa1304369.
- 88 Wainberg ZA, Melisi D, Macarulla T, et al. NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). *J Clin Oncol* 2023;41:LBA661. doi:10.1200/JCO.2023.41.4_suppl.LBA661.
- 89 Ueno H, Ioka T, Ikeda M, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. *J Clin Oncol* 2013;31:1640-8. doi:10.1200/JCO.2012.43.3680.
- 90 Oettle H, Riess H, Stieler JM, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. *J Clin Oncol* 2014;32:2423-9. doi:10.1200/JCO.2013.53.6995.
- 91 Gill S, Ko Y-J, Cripps C, et al. PANCREOX: a randomized phase III study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. *J Clin Oncol* 2016;34:3914-20. doi:10.1200/JCO.2016.68.5776.
- 92 Wang-Gillam A, Li CP, Bodoky G, et al. NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. *Lancet* 2016;387:545-57. doi:10.1016/S0140-6736(15)00986-1.
- 93 Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. *N Engl J Med* 2019;381:317-27. doi:10.1056/NEJMoa1903387.
- 94 Kindler HL, Hammel P, Reni M, et al. Overall survival results from the polo trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. *J Clin Oncol* 2022;40:3929-39. doi:10.1200/JCO.21.01604.
- 95 Reiss KA, Mick R, Teitelbaum U, et al. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial. *Lancet Oncol* 2022;23:1009-20. doi:10.1016/S1470-2045(22)00369-2.
- 96 Dahan L, Williet N, Le Malicot KP, et al. RODIGE 35 Investigators/ Collaborators. Randomized phase II trial evaluating two sequential treatments in first line of metastatic pancreatic cancer: results of the PANOPTIMOX-PRODIGE 35 trial. *J Clin Oncol* 2021;39:3242-50. doi:10.1200/JCO.20.03329.
- 97 Neoptolemos JP, Dunn JA, Stocken DD, et al. European Study Group for Pancreatic Cancer. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. *Lancet* 2001;358:1576-85. doi:10.1016/S0140-6736(01)06651-X.
- 98 Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. *JAMA* 2013;310:1473-81. doi:10.1001/jama.2013.279201.
- 99 Neoptolemos JP, Stocken DD, Bassi C, et al. European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. *JAMA* 2010;304:1073-81. doi:10.1001/jama.2010.1275.
- 100 Sinn M, Bahr M, Liersch T, et al. CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial. *J Clin Oncol* 2017;35:3330-7. doi:10.1200/JCO.2017.72.6463.
- 101 Neoptolemos JP, Palmer DH, Ghaneh P, et al. European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. *Lancet* 2017;389:1011-24. doi:10.1016/S0140-6736(16)32409-6.
- 102 Conroy T, Castan F, Lopez A, et al. Canadian Cancer Trials Group and the Unicancer-GI-PRODIGE Group. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer. *JAMA Oncol* 2022;8:1571-8. doi:10.1001/jamaoncol.2022.3829.
- 103 Tempero MA, Pelzer U, O'Reilly EM, et al. APACT Investigators. Adjuvant nab-paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label, phase III trial. *J Clin Oncol* 2023;41:2007-19. doi:10.1200/JCO.22.01134.
- 104 Uesaka K, Boku N, Fukutomi A, et al. JASPAC 01 Study Group. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). *Lancet* 2016;388:248-57. doi:10.1016/S0140-6736(16)30583-9.
- 105 Sugawara T, Rodriguez Franco S, Sherman S, et al. Association of adjuvant chemotherapy in patients with resected pancreatic adenocarcinoma after multiagent neoadjuvant chemotherapy. *JAMA Oncol* 2023;9:316-23. doi:10.1001/jamaoncol.2022.5808.
- 106 Adam MA, Nassour I, Hoehn R, et al. Neoadjuvant chemotherapy for pancreatic adenocarcinoma lessens the deleterious effect of omission of adjuvant chemotherapy. *Ann Surg Oncol* 2021;28:3800-7. doi:10.1245/s10434-020-09446-x.
- 107 Raufi AG, Manji GA, Chabot JA, Bates SE. Neoadjuvant treatment for pancreatic cancer. *Semin Oncol* 2019;46:19-27. doi:10.1053/j.seminoncol.2018.12.002.
- 108 Heinrich S, Pestalozzi BC, Schäfer M, et al. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. *J Clin Oncol* 2008;26:2526-31. doi:10.1200/JCO.2007.15.5556.

- 109 O'Reilly EM, Perelshteyn A, Jarnagin WR, et al. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. *Ann Surg* 2014;260:142-8. doi:10.1097/SLA.0000000000000251.
- 110 Versteijne E, Suker M, Groothuis K, et al. Dutch Pancreatic Cancer Group. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III preopanc trial. *J Clin Oncol* 2020;38:1763-73. doi:10.1200/JCO.19.02274.
- 111 Versteijne E, van Dam JL, Suker M, et al. Dutch Pancreatic Cancer Group. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. *J Clin Oncol* 2022;40:1220-30. doi:10.1200/JCO.21.02233.
- 112 Ghaneh P, Palmer D, Cicconi S, et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. *Lancet Gastroenterol Hepatol* 2022. doi:10.1016/S2468-1253(22)00348-X.
- 113 Reni M, Balzano G, Zanon S, et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. *Lancet Gastroenterol Hepatol* 2018;3:413-23. doi:10.1016/S2468-1253(18)30081-5.
- 114 Satoi S, Unno M, Motoi F, et al. The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (randomized phase II/III trial; Prep-02/JSP-05). *J Clin Oncol* 2019;37:4126. doi:10.1200/JCO.2019.37.15_suppl.4126.
- 115 Sohal DPS, Duong M, Ahmad SA, et al. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma. *JAMA Oncol* 2021;7:421-7. doi:10.1001/jamaoncol.2020.7328.
- 116 Labori KJ, Brattlie SO, Björserud C, et al. Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: a multicentre randomized phase-II trial (NORPACT-1). *J Clin Oncol* 2023;41:LBA4005. doi:10.1200/JCO.2023.41.17_suppl.LBA4005.
- 117 Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. *Lancet Oncol* 2016;17:801-10. doi:10.1016/S1470-2045(16)00172-8.
- 118 Philip PA, Lacy J, Portales F, et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. *Lancet Gastroenterol Hepatol* 2020;5:285-94. doi:10.1016/S2468-1253(19)30327-9.
- 119 Kunzmann V, Siveke JT, Algül H, et al. German Pancreatic Cancer Working Group (AIO-PAK) and NEOLAP investigators. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. *Lancet Gastroenterol Hepatol* 2021;6:128-38. doi:10.1016/S2468-1253(20)30330-7.
- 120 Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. *Ann Surg* 2006;244:10-15. doi:10.1097/01.sla.0000217673.04165.ea.
- 121 Ratnayake B, Pendharkar SA, Connor S, et al. Patient volume and clinical outcome after pancreatic cancer resection: A contemporary systematic review and meta-analysis. *Surgery* 2022;172:273-83. doi:10.1016/j.surg.2021.11.029.
- 122 van Dongen JC, Wismans LV, Suurmeijer JA, et al. The effect of preoperative chemotherapy and chemoradiotherapy on pancreatic fistula and other surgical complications after pancreatic resection: a systematic review and meta-analysis of comparative studies. *HPB (Oxford)* 2021;23:1321-31. doi:10.1016/j.hpb.2021.04.027.
- 123 van Dongen JC, Suker M, Versteijne E Dutch Pancreatic Cancer Group. Surgical complications in a multicenter randomized trial comparing preoperative chemoradiotherapy and immediate surgery in patients with resectable and borderline resectable pancreatic cancer (PREOPANC Trial). *Ann Surg* 2022;275:979-84. doi:10.1097/SLA.0000000000004313.
- 124 Bachellier P, Addeo P, Faitot F, Nappo G, Dufour P. Pancreatectomy with arterial resection for pancreatic adenocarcinoma: how can it be done safely and with which outcomes?: a single institution's experience with 118 patients. *Ann Surg* 2020;271:932-40. doi:10.1097/SLA.00000000000003010.
- 125 Nigri G, Petrucciani N, Belloni E, et al. Distal pancreatectomy with celiac axis resection: systematic review and meta-analysis. *Cancers (Basel)* 2021;13:1967. doi:10.3390/cancers13081967.
- 126 Loos M, Kester T, Klaiber U, et al. Arterial resection in pancreatic cancer surgery: effective after a learning curve. *Ann Surg* 2022;275:759-68. doi:10.1097/SLA.00000000000004054.
- 127 Gemenetzi G, Groot VP, Blair AB, et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. *Ann Surg* 2019;270:340-7. doi:10.1097/SLA.0000000000002753.
- 128 Lee M, Kang JS, Kim H, et al. Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. *J Hepatobiliary Pancreat Sci* 2023;30:111-21. doi:10.1002/jhpb.1050.
- 129 De Simoni O, Scarpa M, Tonello M, et al. Oligometastatic pancreatic cancer to the liver in the era of neoadjuvant chemotherapy: which role for conversion surgery? A systematic review and meta-analysis. *Cancers (Basel)* 2020;12:3402. doi:10.3390/cancers12113402.
- 130 Sakaguchi T, Valente R, Tanaka K, Satoi S, Del Chiaro M. Surgical treatment of metastatic pancreatic ductal adenocarcinoma: A review of current literature. *Pancreatol* 2019;19:672-80. doi:10.1016/j.pan.2019.05.466.
- 131 Hank T, Klaiber U, Hinze U, et al. Oncological outcome of conversion surgery after preoperative chemotherapy for metastatic pancreatic cancer. *Ann Surg* 2022;277:e1089-98. doi:10.1097/SLA.0000000000005481.
- 132 Wang M, Li D, Chen R, et al. Minimally Invasive Treatment Group in the Pancreatic Disease Branch of China's International Exchange and Promotion Association for Medicine and Healthcare (MITG-P-CPAM). Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial. *Lancet Gastroenterol Hepatol* 2021;6:438-47. doi:10.1016/S2468-1253(21)00054-6.
- 133 Vissers FL, van Hilst J, Burdío F, et al. International Minimally Invasive Pancreatic Resection Trialists Group. Laparoscopic versus open pancreatoduodenectomy: an individual participant data meta-analysis of randomized controlled trials. *HPB (Oxford)* 2022;24:1592-9. doi:10.1016/j.hpb.2022.02.005.
- 134 Da Dong X, Felsenreich DM, Gogna S, et al. Robotic pancreaticoduodenectomy provides better histopathological outcomes as compared to its open counterpart: a meta-analysis. *Sci Rep* 2021;11:3774. doi:10.1038/s41598-021-83391-x.
- 135 Kabir T, Tan HL, Syn NL, Wu EJ, Kam JH, Goh BKP. Outcomes of laparoscopic, robotic, and open pancreatoduodenectomy: A network meta-analysis of randomized controlled trials and propensity score matched studies. *Surgery* 2022;171:476-89. doi:10.1016/j.surg.2021.07.020.
- 136 Fu Y, Qiu J, Yu Y, Wu D, Zhang T. Meta-analysis of robotic versus open pancreatoduodenectomy in all patients and pancreatic cancer patients. *Front Surg* 2022;9:989065. doi:10.3389/fsurg.2022.989065.
- 137 Ouyang L, Zhang J, Feng Q, Zhang Z, Ma H, Zhang G. Robotic versus laparoscopic pancreaticoduodenectomy: an up-to-date system review and meta-analysis. *Front Oncol* 2022;12:834382. doi:10.3389/fonc.2022.834382.
- 138 Kamarajah SK, Bundred J, Marc OS, et al. Robotic versus conventional laparoscopic pancreaticoduodenectomy: a systematic review and meta-analysis. *Eur J Surg Oncol* 2020;46:6-14. doi:10.1016/j.ejso.2019.08.007.
- 139 Cucchetti A, Bocchino A, Crippa S, et al. Advantages of laparoscopic distal pancreatectomy: Systematic review and meta-analysis of randomized and matched studies. *Surgery* 2022. doi:10.1016/j.surg.2022.11.029.
- 140 Abu Hilal M, Korrel M, Jones L, et al. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised trial. *J Clin Oncol* 2023;41:4163. doi:10.1200/JCO.2023.41.16_suppl.4163.
- 141 Tchelebi LT, Lehrer EJ, Trifiletti DM, et al. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRISP): An international systematic review and meta-analysis. *Cancer* 2020;126:2120-31. doi:10.1002/cncr.32756.
- 142 Palta M, Godfrey D, Goodman KA, et al. Radiation therapy for pancreatic cancer: executive summary of an ASTRO clinical practice guideline. *Pract Radiat Oncol* 2019;9:322-32. doi:10.1016/j.pro.2019.06.016.
- 143 Van Laethem JL, Hammel P, Mornex F, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. *J Clin Oncol* 2010;28:4450-6. doi:10.1200/JCO.2010.30.3446.
- 144 Ma T, Bai X, Wei Q, et al. Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, randomized, open-label, single center trial. *BMC Cancer* 2022;22:865. doi:10.1186/s12885-022-09974-7.
- 145 Stocken DD, Büchler MW, Dervenis C, et al. Pancreatic Cancer Meta-analysis Group. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. *Br J Cancer* 2005;92:1372-81. doi:10.1038/sj.bjc.6602513.
- 146 Mornex F, Girard N, Scoazec JY, et al. Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial. *Int J Radiat Oncol Biol Phys* 2006;65:1471-8. doi:10.1016/j.ijrobp.2006.02.054.

- 147 Small WJr, Berlin J, Freedman GM, et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. *J Clin Oncol* 2008;26:942-7. doi:10.1200/JCO.2007.13.9014.
- 148 Xu CP, Xue XJ, Liang N, et al. Effect of chemoradiotherapy and neoadjuvant chemoradiotherapy in resectable pancreatic cancer: a systematic review and meta-analysis. *J Cancer Res Clin Oncol* 2014;140:549-59. doi:10.1007/s00432-013-1572-4.
- 149 Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma. *JAMA Oncol* 2018;4:963-9. doi:10.1001/jamaoncol.2018.0329.
- 150 Katz MHG, Shi Q, Meyers J, et al. Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas. *JAMA Oncol* 2022;8:1263-70. doi:10.1001/jamaoncol.2022.2319.
- 151 Janssen QP, van Dam JL, Kivits IG, et al. Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. *Ann Surg Oncol* 2021;28:8297-308. doi:10.1245/s10434-021-10276-8.
- 152 Loehrer PJSr, Feng Y, Cardenas H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. *J Clin Oncol* 2011;29:4105-12. doi:10.1200/JCO.2011.34.8904.
- 153 Hammel P, Huguet F, van Laethem J-L, et al. LAP07 Trial Group. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib. *JAMA* 2016;315:1844-53. doi:10.1001/jama.2016.4324.
- 154 Chaffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. *Ann Oncol* 2008;19:1592-9. doi:10.1093/annonc/mdn281.
- 155 Suker M, Nuytens JJ, Eskens FALM, et al. Efficacy and feasibility of stereotactic radiotherapy after folfoxin in patients with locally advanced pancreatic cancer (LAPC-1 trial). *EclinicalMedicine* 2019;17:100200. doi:10.1016/j.eclinm.2019.10.013.
- 156 Fietkau R, Ghadimi M, Grützmann R, et al. Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: first results of the CONKO-007 trial. *J Clin Oncol* 2022;40:4008. doi:10.1200/JCO.2022.40.16_suppl.4008.
- 157 Strauss VY, Shaw R, Virdee PS, et al. Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2). *BMC Cancer* 2019;19:121. doi:10.1186/s12885-019-5307-z.
- 158 Oar A, Lee M, Le H, et al. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. *BMC Cancer* 2021;21:936. doi:10.1186/s12885-021-08666-y.
- 159 Portales F, Ychou M, Samalin E, et al. Sequential treatment with gemcitabine/nab-paclitaxel (GA) and FOLFIRINOX (FFX) followed by stereotactic MRI-guided adaptive radiation therapy (SMART) in patients with locally advanced pancreatic cancer (LAPC): GABRINOX-ART phase 2, multicenter trial. *J Clin Oncol* 2022;40:TPS4191. doi:10.1200/JCO.2022.40.16_suppl.TPS4191.
- 160 Álvaro Sanz E, Garrido Siles M, Rey Fernández L, Villatoro Roldán R, Rueda Domínguez A, Abilés J. Nutritional risk and malnutrition rates at diagnosis of cancer in patients treated in outpatient settings: Early intervention protocol. *Nutrition* 2019;57:148-53. doi:10.1016/j.nut.2018.05.021.
- 161 Na B-G, Han S-S, Cho Y-A, et al. Nutritional status of patients with cancer: a prospective cohort study of 1,588 hospitalized patients. *Nutr Cancer* 2018;70:1228-36. doi:10.1080/01635581.2019.1578392.
- 162 Griffin OM, Bashir Y, O'Connor D, et al. Measurement of body composition in pancreatic cancer: a systematic review, meta-analysis, and recommendations for future study design. *Dig Surg* 2022;39:141-52. doi:10.1159/000524575.
- 163 Ozola Zalīte I, Zykus R, Francisco Gonzalez M, et al. Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review. *Pancreatol* 2015;15:19-24. doi:10.1016/j.pan.2014.11.006.
- 164 Heckler M, Klaiber U, Hüttner FJ, et al. Prospective trial to evaluate the prognostic value of different nutritional assessment scores for survival in pancreatic ductal adenocarcinoma (NURIMAS Pancreas SURVIVAL). *J Cachexia Sarcopenia Muscle* 2021;12:1940-7. doi:10.1002/jcsm.12796.
- 165 Hamauchi S, Furuse J, Takano T, et al. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. *Cancer* 2019;125:4294-302. doi:10.1002/cncr.32406.
- 166 Temel JS, Abernethy AP, Currow DC, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. *Lancet Oncol* 2016;17:519-31. doi:10.1016/S1470-2045(15)00558-6.
- 167 Solheim TS, Laird BJA, Balstad TR, et al. A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. *J Cachexia Sarcopenia Muscle* 2017;8:778-88. doi:10.1002/jcsm.12201.
- 168 Koulouris AI, Alexandre L, Hart AR, Clark A. Endoscopic ultrasound-guided celiac plexus neurolysis (EUS-CPN) technique and analgesic efficacy in patients with pancreatic cancer: A systematic review and meta-analysis. *Pancreatol* 2021;21:434-42. doi:10.1016/j.pan.2020.12.016.
- 169 Kim CA, Lelond S, Daeninck PJ, et al. The impact of early palliative care on the quality of life of patients with advanced pancreatic cancer: The IMPERATIVE case-crossover study. *Support Care Cancer* 2023;31:250. doi:10.1007/s00520-023-07709-3.
- 170 Erstad DJ, Sojoodi M, Taylor MS, et al. Fibrotic response to neoadjuvant therapy predicts survival in pancreatic cancer and is measurable with collagen-targeted molecular MRI. *Clin Cancer Res* 2020;26:5007-18. doi:10.1158/1078-0432.CCR-18-1359.
- 171 Biffi G, Oni TE, Spielman B, et al. IL1-induced JAK/STAT signaling is antagonized by TGFβ to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. *Cancer Discov* 2019;9:282-301. doi:10.1158/2159-8290.CD-18-0710.
- 172 Veldhuijzen van Zanten SEM, Pieterman KJ, Wijnhoven BPL, et al. FAPI PET versus FDG PET, CT or MRI for staging pancreatic, gastric- and cholangiocarcinoma: systematic review and head-to-head comparisons of diagnostic performances. *Diagnostics (Basel)* 2022;12:1958. doi:10.3390/diagnostics12081958.
- 173 Gao Y, Cheng S, Zhu L, et al. A systematic review of prognosis predictive role of radiomics in pancreatic cancer: heterogeneity markers or statistical tricks? *Eur Radiol* 2022;32:8443-52. doi:10.1007/s00330-022-08922-0.
- 174 Fu Q, Chen Y, Huang D, et al. Randomized phase III study of sintilimab in combination with modified folfoxin versus folfoxin alone in patients with metastatic and recurrent pancreatic cancer in China: the CISP3 trial. *J Clin Oncol* 2022;40:560. doi:10.1200/JCO.2022.40.4_suppl.560.
- 175 Columbus G. Nivolumab/cabiralizumab combo misses PFS endpoint in pancreatic cancer. 2020. <https://www.onclive.com/view/nivolumabcabiralizumab-combo-misses-pfs-endpoint-in-pancreatic-cancer>
- 176 Wang-Gillam A, O'Reilly EM, Bendell JC, et al. A randomized phase II study of cabiralizumab (cabira) + nivolumab (nivo) ± chemotherapy (chemo) in advanced pancreatic ductal adenocarcinoma (PDAC). *J Clin Oncol* 2019;37:4. doi:10.1200/JCO.2019.37.4_suppl.TPS465.
- 177 Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. *Nature* 2023;618:144-50. doi:10.1038/s41586-023-06063-y.
- 178 Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. *Cancer Cell* 2017;32:185-203.e13. doi:10.1016/j.ccell.2017.07.007.
- 179 Strickler JH, Satake H, George TJ, et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. *N Engl J Med* 2023;388:33-43. doi:10.1056/NEJMoa2208470.
- 180 Bekaii-Saab TS, Spira AI, Yaeger R, et al. KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation. *J Clin Oncol* 2022;40:519. doi:10.1200/JCO.2022.40.4_suppl.519.
- 181 Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. *Lancet Oncol* 2015;16:e498-509. doi:10.1016/S1470-2045(15)00007-8.
- 182 Twyman-Saint Victor C, Rech AJ, Maitly A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. *Nature* 2015;520:373-7. doi:10.1038/nature14292.
- 183 Antonia SJ, Villegas A, Daniel D, et al. PACIFIC Investigators. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. *N Engl J Med* 2018;379:2342-50. doi:10.1056/NEJMoa1809697.
- 184 Chen IM, Johansen JS, Theille S, et al. Randomized phase II study of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy for refractory metastatic pancreatic cancer (CheckPAC). *J Clin Oncol* 2022;40:3180-9.